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ABSTRACT
The aortic heart valve regulates blood flow as it exits the heart and enters the body; when
this valve malfunctions it creates serious health problems. While current valve
replacement options are satisfactory, the ultimate goal is to create a living valve
replacement that can self repair, regenerate and remodel as the patient grows. An
approach is via tissue engineering, which uses principles from engineering and cell
biology to create functional tissue substitutes for in vivo replacement. This study aims at
fabricating nanofibrillar scaffolds by coaxial electrospinning for the treatment of valvular
disease. Many electrospun biopolymers promote cell adhesion, but lack the necessary
signals that encourage cell proliferation and migration. The objectives of this work are to
create a bioactive scaffold by encapsulating therapeutic proteins within a polymer shell
and to analyze the protein release kinetics. By incorporating growth factors into the
nanofibres, controlled release within the scaffold may be achieved and biochemical cues
for tissue regeneration can be signaled. Samples were analyzed using scanning electron
microscopy, transmission electron microscopy and laser scanning confocal microscopy.
Core-shell nanofibres composed of poly(caprolactone) (PCL) and encapsulated bovine
serum albumin (BSA) were successfully prepared and had an average diameter of
diameter of 1069 ± 388 nm. Electrospun PCL-BSA scaffold containing 62.7 ± 5.7 pg of
BSA were able to release 35.33 ± 2.23 % of the theoretical loaded protein over 10 days.
Furthermore, a method for isolating and purifying type I collagen from rat tails was
developed and solid collagen fibres were prepared with an average diameter of 256 ± 48
nm. Core-shell nanofibres composed of type I collagen and encapsulated BSA with
average inner and outer fibre diameters of 87 ± 33 nm and 204 ±73 nm, respectively.

Keywords: aortic heart valve, tissue engineering, coaxial electrospinning, controlled
release, poly (e-caprolactone), type I collagen
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Chapter 1: Introduction
Aortic heart valve replacements have been heavily studied over the past fifty years, and
yet an ideal valve replacement still does not exist. An ideal valve replacement should be
biocompatible, non-thrombogenic and offer continuous remodeling and repair to grow
with the patient [1]. Tissue engineering provides a promising alternative for the
development of tissue replacements; the key support structure used for tissue
regeneration is the scaffold. A new form of biomaterials being developed are smart
materials, which intuitively provide physical and biological cues necessary for tissue
regeneration [2]. These smart materials often combine the design of a tissue structure
coupled with the delivery of biologically active compounds.

One method for creating suitable scaffolds for tissue engineering is by electrospinning.
Electrospinning creates continuous, non-woven nanofibrous 3D meshes with fibres in
either a random or ordered orientation. Moreover, therapeutic proteins can be
encapsulated within the polymer fibres via coaxial electrospinning. Many electrospun
polymer fibres promote cell adhesion, yet cannot provide the necessary signals for cell
proliferation, migration and differentiation, which is crucial for the success of a tissue
engineered implant [3]. By incorporating therapeutic proteins called growth factors into
the nanofibres, controlled release within the scaffold may be achieved, signalling
essential cues for tissue development [2].

This work aims at the creation of a unique core-shell growth factor containing
nanofibrous scaffold that is anticipated to provide optimal conditions to control and guide
tissue formation. An understanding of growth factor delivery from the scaffold is
important for developing systems that accurately reflect the growth factor concentrations
in native tissue [4]. The scaffold will be considered in the design and fabrication of a
tissue engineered heart valve replacement that promises to be a living implant with the
ability to regenerate and grow with the patient.
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The main focus of this work is to create a foundation for the development of a bioactive
scaffold capable of localized drug delivery by encapsulating various therapeutic
substances within core-shell nanofibres. This will be accomplished using coaxial
electrospinning and the release kinetics will be examined.

The main objectives of this work are:
•

To encapsulate proteins within core-shell nanofibres composed of Poly (£caprolactone) (PCL) via coaxial electrospinning

•

To analyze the release of Bovine Serum Albumin (BSA) from core-shell PCL
fibres using the Bradford Assay

•

To develop a method to measure the release of Platelet Derived Growth Factor
(PDGF) from PCL core-shell fibres using Enzyme Linked Immunosorbent Assay
(ELISA)

•

To analyze the biocompatibility of PCL core-shell scaffolds in-vitro using porcine
Radial Artery Cells (RACs)

•

To isolate and purify type I collagen from rat tails

•

To electrospin solid and hollow fibres composed of type I collagen
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Chapter 2: Background and Literature Review
2.1 The Aortic Heart Valve
2.1.1 Structure and Function
The heart is an organ used to circulate blood throughout the body. It is composed of four
chambers that are connected by heart valves. These valves are used to maintain
unidirectional blood flow through the heart during the cardiac cycle. The aortic heart
valve (AHV) is a semi-lunar valve composed of three leaflets and is located between the
left ventricle and the aorta.

Figure 2.1: AHV leaflets during valve (a) opening and (b) closing. Reprinted with
permission from [5],
The leaflets are flaps of connective tissue that create a seal, preventing regurgitation of
blood back into the heart (Figure 2.1) [5]. The unique three layered structure of the
leaflets allows them to withstand repetitive mechanical stresses over time. The layer
facing the inside of the heart is called the ventricularis, and is composed of randomly
orientated collagen fibres and radially aligned elastin fibres (Figure 2.2b). The abundance
of elastin in the ventricularis is what gives the leaflet the ability to extend and recoil [5].
The spongiosa, the central layer, is a gelatinous lamina composed of glycosaminoglycans
(GAGs). This layer contains a large amount of water and is responsible for absorbing and
cushioning the compressive forces during the cardiac cycle [6]. Finally, the fibrosa faces
the outside of the heart and is composed of circumferentially aligned, crimped collagen
nanofibres (Figure 2.2a). This arrangement confers the valve its durable mechanical
properties and acts as the load-bearing portion of the tissue [7].
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Figure 2.2: Images of the aortic heart valve leaflet tri-layered structure. Images of the a)
fibrosa and b) ventricularis of a bovine aortic valve leaflet. Scale bar is 1 cm. (Reprinted
with permission from [8]).
2.1.2 Disease and Treatment
Valvular heart disease continues to play a significant role in cardiovascular morbidity and
mortality. The most prevalent forms of AHV disease include congenital AHV
deformation, aortic stenosis and aortic regurgitation [9]. Congenital AHV disease is
present in ~1% of the population and is characterized by a malformation of the valve
resulting in a total or partial absence of one or more leaflets [5]. This in turn can cause
stenosis, narrowing of the valve opening, and/or regurgitation, backflow of blood into the
heart [10]. Aortic valve stenosis is a degenerative disease characterized by calcification
and stiffening of leaflet tissue, and in effect it decreases the valve orifice area; aortic
regurgitation is characterized by improper valve closing, which causes blood back flow
into the heart [10-11].

Treatment of AHV disease includes valve repair or replacement; however, valve repair is
not commonly recommended because of irreversible damage sustained by the valve and
ineffective methods for supporting the damaged tissue [10]. Valve replacement is one of
the most common surgical procedures with 87,000 heart valve replacement performed
annually, accounting for 12% of all open heart procedures done in the U.S. (2000), and
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275,000-370,000 aortic valve replacement surgeries are performed globally each year [9,
12]. Current valve replacements include bioprosthetic and mechanical valves (Figure
2.3); however, both designs have associated problems [1, 13],

Figure 2.3: Examples of bioprosthetic (left - Sorin Mitroflow Aortic Pericardial Heart
Valve) and mechanical (right - Sorin Bicarbon Overline Heart Valve) AHV prostheses.
Scale bar is 1 cm.
Mechanical valve replacements are generally made of pyrolytic carbon or metals coated
with pyrolytic carbon, and are organized into folding discs anchored by hinges. This
geometry creates several problems resulting in poor hemodynamics, platelet activation
and thrombolytic complications [14],

As a result, patients are required to be on

anticoagulants to avoid clot formation; however, this creates an additional risk of anti
coagulant induced haemorrhaging, which accounts for ~2 % of adverse events associated
with AHV replacement [14].

Bioprosthetic valves are a viable substitute, but their use is limited due to poor long-term
durability [15]. Current bioprosthetic valve designs include glutaraldehyde fixed
decellularized porcine aortic heart valve or glutaraldehyde fixed bovine pericardium
mounted onto a stent. Tissue valves are subject to higher rates of tissue degradation and
calcification relative to mechanical or native valves, and it is thought to be caused by
remaining cell debris and glutaraldehyde [15]. These designs unfortunately all have
limited durability related to their acellular nature, calcification and their inability to
repair, remodel or grow with the patient.
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2.2 Electrospinning
2.2.1 Fundamentals
Electrospinning was first patented in 1934 by Formhals, and is a technique used to create
non-woven, submicron fibres by extruding a polymer solution from a spinneret in the
presence of an electric field [16]. Due to the simplicity and versatility of electrospinning,
several natural and synthetic polymers have been successfully electrospun for a variety of
applications including textiles, wound dressings, drug delivery and tissue engineering
scaffolds [17-24],
Metal Needle

Voltage Supply
-------- -- — !►

Syringe Pump
Figure 2.4: Typical electrospinning setup including syringe pump, syringe with metal
needle, metal collecting plate and a power supply.
Electrospinning has been extensively studied and the general setup includes a syringe
filled with polymer solution, metal needle, voltage supply, metal collector and syringe
pump (Figure 2.4) [17-25, 27-34]. The polymer solution is extruded through the metal
needle at a flow rate controlled by the syringe pump. The voltage supply is connected to
the metal needle and grounded collecting plate and creates an electric field between them.
As the polymer solution is extruded from the needle, the electric field induces charge
along the surface of the droplet, creating a force opposite the surface tension [25]. As the
charge density increases, the droplet becomes extended and forms a conical structure
called the Taylor Cone (Figure 2.5) [26]. At a critical voltage, a single polymer jet is
ejected from the cone surface and undergoes a series of whipping instabilities and, as the
solvent evaporates, deposits non-woven nanofibres on the collector [27-28].
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Figure 2.5: Polymer solution droplet at the needle tip developing into the Taylor cone
under increasing electric field.
2.2.2 Parameters of Interest
There are several parameters that can be manipulated during the electrospinning process
that can influence fibre morphology. These parameters are divided into three groups [19]:
— Process conditions, which includes applied voltage, flow rate and the distance
between the collector and spinneret
— Solution properties, including the viscosity, concentration and conductivity of the
polymer solution; and
— Ambient parameters like temperature and humidity
These variables have been independently studied to examine how they influence fibre
diameter, diameter distribution and fibre morphology; the results are summarized in
Table 2.1. An unfavourable morphology that can result during electrospinning is called
beading, which occurs when the ejected polymer jet is still fluid and wet when it hits the
collector [29]. Beading occurs because the charge on the surface of the jet dissipates,
decreasing the elongation force, creating fibres have a “bead-on-string” appearance as
seen in Figure 2.6 [30].

Figure 2.6: SEM images illustrating electrospun polyamide-6 fibres with (a) and without
beading (b). Scale bar are 10 pm and 1 pm for a and b respectively. (Reproduced with
permission from [31 ])
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Table 2.1 - Summary of Parameters and Associated Effects during Electrospinning
Process Parameters
Distance

— Critical distance exists for fibres to dry before they reach the
collector [32]
- Below or above this distance beading will occur [24]
-

Voltage

Flow Rate

Increases in voltage past the threshold cause the Taylor cone to
dissipate into the needle causing beading [18]
— Further increases cause splaying, which creates an ambiguous
effect on the fibre diameter and diameter distribution [33]
-

Increased flow rates lead to larger diameters [33]
Low flow rates decrease beading and fibre diameter [24]
Solution Parameters

Concentration

-

Conductivity
-

Has the strongest influence on fibre diameter [24]
Fibre diameter increases with concentration according to a
power law [18]
If the concentration is too low electrospraying will occur [31]
Increases in conductivity, increase the charge density and as a
result decrease fibre diameter [33]
Increases in conductivity also decrease beading [29]
Ambient Parameters

Temperature

Humidity

-

Increased temperature decreases the fibre diameter [ 19]
Thought to be related to changes in viscosity [31 ]

-

Increased humidity leads to larger fibre diameters [ 19]
Increases in humidity can lead to pore formation on surface of
fibres[34]

2.2.3 Fibre Orientation
Electrospinning is unique in that the orientation and the degree of alignment between
fibres can be manipulated by the type of collector used [35]. Alignment is important
because most native tissues have a defined spatial arrangement that is significant for
function, like that of AHV leaflets. Incorporation of nanostructures onto scaffolds can be
used to encourage and guide cell behaviour; a scaffold composed of aligned nanofibres
would instinctively provide this informational guidance, and eliminate the need for post
spinning processing [36].
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a) Parallel Plates

b) Rotating Drum

c) Rotating Disc

Figure 2.7: Different types of electrospinning collectors used to create aligned fibres.
There are currently three main types of collectors used to generate aligned fibres: parallel
plates, rotating drums and rotating discs (Figure 2.7). Parallel plates are composed of two
grounded conductive plates that capture aligned fibres between them; a drawback for this
method is that the fibre length is limited to the distance between the plates [37-38]. The
other two methods are a rotating drum or disc, where the speed of rotation influences the
degree of alignment between fibres [39-40], The collectors need to be moving fast
enough to align the fibres, but not so fast that it breaks the fibres as they are being
collected [41-42]. A rotating drum has benefits because they come in different shapes and
sizes, which can influence fibre alignment and diameter, and provides a larger area for
fibre collection [24]. Fibres can be collected on a rotating disc two ways: directly on the
disc’s edge with a yam-like structure or on a glass cover slip attached to the disc’s edge
[43]. The development of new collectors has been investigated; for example, a study used
a rotating wire mandrel to produce self-crimping nanofibres, which had similar structural
and mechanical properties to that of native collagen fibrils, like in AHV leaflets [44].

2.2.4 Coaxial Electrospinning
Coaxial electrospinning creates hollow, or core-shell, nanofibres that can be used to
encapsulate various substances. Core-shell nanofibres have applications in microfluidics,
textiles and fabrics, and drug delivery [45-47, 21]. Initially proposed by Loscertales et al.,
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coaxial electrospinning modifies the traditional set-up by having two solutions feed into
one spinneret concentrically via capillary tubing as can be seen in Figure 2.8 [48].

Collector'—
Figure 2.8: Schematic diagram of coaxial electrospinning setup illustrating the
concentric spinneret and fibre structure (Adapted from [45]).
The parameters that influence fibre morphology during electrospinning have the same
trend in coaxial electrospinning; however, there are new variables that need to be
considered. In coaxial electrospinning the two solutions meet at the tip of the needle, and
how they interact here can influence fibre structure. If the two solutions are immiscible a
more defined core-shell structure can be produced; otherwise, mixing can occur and the
core-shell structure is lost and beading occurs [45, 47]. Furthermore, the ratio of the core
and shell solution flow rates can influence the ability to produce hollow fibres. It has
been demonstrated that the optimal core-shell ratio should be between 1:3-1:6 [21, 49].
Ratios below this range do not provide enough shell polymer solution to encapsulate the
core, and ratios above this range result in collapse of the hollow core [21].

2.3 Tissue Engineering
2.3.1 Principles
Tissue engineering (TE) is commonly understood to be an interdisciplinary field that uses
a combination of engineering principles and life science to develop of in vivo tissue
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substitutes that restore or improve tissue function [50]. The general concept, depicted in
Figure 2.9, involves culturing patient cells from biopsy samples and seeding them onto a
scaffold. Afterwards biological stimulants are incorporated with the scaffold, which is
then prepared in a bioreactor and implanted into the patient [35, 50-51]. Bioactives are
compounds like cytokines or growth factors that regulate cell behaviours like adhesion,
proliferation, migration or differentiation; they are an important part of TE because they
control cell behaviour and tissue regeneration [52]. Recently, it was proposed that the
paradigm be adjusted such that the scaffold is implanted into the patient directly after cell
seeding, exploiting the body as a natural source of bioactive agents and a bioreactor [53
54]. Current examples of clinical tissue engineered prototypes and currently available
products are summarized in Table 2.2.

Incorporate
Bioactives

Figure 2.9: Schematic diagram illustrating the tissue engineering paradigm.
One of the first studies performed with a heart valve replacement composed of synthetic
scaffolding was done by Hoerstrup et al. [55]. A tri-leaflet structure made of
polyfglycolic acid) (PGA) coated with poly-4-hydroxybutyrate (PHB) was prepared via
heat welding. The construct was conditioned in a bioreactor under pulsatile conditions for
14 days and implanted into sheep for up to 20 weeks. The valve replacements were
functioning in-vivo and showed layered organization of collagen and GAGs; however,
during the remodelling process the leaflets thickened, significant amounts of elastin were
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not present and regurgitation occured after 16 weeks. Breuer et al. implanted a single
tissue engineered valve leaflet composed of layered PGA and poly(lactic-co-glycolic
acid) (PGLA) fibres, which were seeded with homologous myofibroblasts and
endothelial cells [56]. They found that the TE valve leaflet had thickened but presented
an ECM similar to that of native valve tissue. A recent study performed by Schmidt et al.
created a poly(L-lactide-co-D,L-lactide) (P(LDL)LA) tri-leaflet mesh by thermal fixation
and coated it with electrospun P(LDL)LA nanofibres to mimic the tri-layered structure of
AHV leaflets [57]. The scaffolds were seeded with autologous bone marrow and
peripheral blood stem cells, cultured in a bioreactor for 7 days and implanted into sheep
for 4 weeks. Again leaflet tissue thickening occurred and elastin was not present, but
stem cells had demonstrated similar phenotypic responses as myofibroblasts and
endothelial cells. These studies establish a precedent for the feasibility of the
development of tri-layered electrospun nanofibrous scaffold for a tissue engineered AHV
leaflet replacement with in-vivo applications.

Table 2.2 - Examples of Current Clinical Tissue Engineered Devices and Prototypes
Applications
Material
Spinal fusion, tibial
INFUSE Bone Graft (Medtronic)
fractures,
and oral
Bovine
type
I
collagen
absorbable
Bone
sponge doped with recombinant human maxillofacial bone grafting
[58]
(Approved 2002)
bone morphogenetic protein
- Decellularized allogeneic tracheal
End-stage airway disease
Trachea
segment seeded with autologous
(Initial trial)
[59]
epithelial cells and chondrocytes
Articular cartilage injury
CaReS (Arthro Kinetics)
Cartilage
(Germany Approved in
- Rat tail type I collagen matrix seeded
[60]
2007)
with autologous chondrocytes
- Composite scaffolds composed of
End-stage bladder disease
collagen and PGA seeded with
Bladder
requiring cystoplasty (Initial
autologous urothelial and smooth
[61]
stages)
muscle cells
ICX-SKN (Intercytex)
Skin grafts (Phase II
Skin
- Allogenic collagen matrix seeded with
Clinical Trials)
[62]
allogenic fibroblasts
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2.3.3 Scaffolds for Tissue Engineering
One of the most critical components of TE is the scaffold: a 3D, artificial structure that
supports cell growth and tissue development [35, 50, 54, 63]. The scaffold acts as an
artificial extracellular matrix (ECM), which is the native fibrillar network composed of
GAGs, proteoglycans and proteins used to support cell growth and influence cell
behaviour [64]. Scaffold design is of particular importance because integration of the
neo-tissue into the native tissue is crucial for success [65]. This implies that the scaffold
has to be biodegradable such that the artificial implant will be completely replaced by
newly formed tissue. Furthermore, the degradation rate of the scaffold should be
controlled such that it closely matches that of matrix formation so that support is
maintained during tissue development [3, 65].

There are significant characteristics to consider when designing a scaffold. It is important
for scaffolds to have a high porosity with suitable pore size, contain nano-scale features
and be capable of elucidating cellular responses. A highly porous scaffold allows for the
efficient transfer of nutrients and wastes between the scaffold and its surrounding
environment [35]. In additions pores should be of sufficient size to allow for cell
migration throughout the 3D network. Electrospun nanofibres are highly porous and have
a large surface area to volume ratio, increasing rates of cell adhesion and migration [66].
The dimensions and scale of a scaffold can also influence cell behaviour. Recently, there
has been a focus on developing 3D scaffolds on the nanoscale because stronger
interactions between the cells and scaffold, and the scaffold and host tissue have been
demonstrated using smaller scale features [36, 54, 66].

Furthermore, the physical and mechanical properties of a scaffold should closely match
those at the implant site such that it may tolerate the forces acting on it and the
surrounding environment upon implantation. This is particularly important for AHV TE,
where the implant will have to be able to withstand the various tensile and compressive
forces accompanying pulsation, pressure gradients and blood flow [51, 66]. Furthermore,
it has been demonstrated that cells can sense the stiffness of the material and respond
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accordingly [67]. Therefore, material selection can be used to influence the scaffold
properties and can effectively guide cell behaviour and cytoskeleton rearrangement [68].

The native ECM plays several roles in tissue development as a support structure for cell
and tissue growth, and as a depot of growth factors and signalling molecules that are
released from the matrix to regulate cell behaviour [65, 69]. Many electrospun synthetic
biodegradable polymers promote cell adhesion, yet cannot provide the necessary
biochemical signals to control and guide tissue regeneration [3, 63]. Recently, the
concept of instructive materials has been popularized, where the material is loaded with
information to properly guide gene expression, cell migration and differentiation, like the
native ECM [63-64]. This can be achieved through a variety of methods including
manipulation of the scaffolds mechanical properties, surface functionalization with
bioactive molecules (like RGD peptides), incorporation of matricellular components
(collagen, laminin etc.) or controlled release of signalling molecules from the scaffold [3,
36, 53, 54, 65, 67]. Electrospun nanofibrous meshes are a promising choice for TE
scaffolds because they fulfill most of these structural, physical and biological
requirements.

2.4 Controlled Release
2.4.1 Drug Delivery Systems
Controlled drug delivery systems (DDS) are designed to release therapeutic substances at
a predetermined rate.

Controlled delivery offers several important advantages over

conventional drug therapies in terms of drug administration, biodistribution and safety
[70]. Controlled DDS help maintain the drug concentration in the therapeutic range,
which exists between the toxic level and the minimum effective level (Figure 2.10). Also,
controlled release improves regulation of drug dosage resulting in higher patient
compliancy and less side effects [71].
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Figure 2.10: Drug release profiles comparing conventional multiple dose therapy (dashed
line) with sustained release profile (solid line).
DDS can protect biologically sensitive molecules and thus preserve medications that are
rapidly destroyed by the body, increasing bioavailability at the target site. Furthermore,
controlled drug delivery offer localized delivery of the drug to a specific portion of the
body, decreasing systemic side effects [72]. Some examples of polymeric DDS include
diffusion based systems (reservoirs and matrices), erosion or chemical controlled systems
(degradation or bond-cleavage) and solvent activated systems (hydrogels) [70-71].

Electrospun nanofibres are currently being investigated as controlled release DDS (Table
2.3) for applications in gene therapy, antibiotic wound dressings and TE [73, 65, 21, 22,
74]. There are two methods in which therapeutic substances can be incorporated into
electrospun polymer fibres: blending or coaxial electrospinning. Blend electrospinning
involves mixing the polymer and the drug into one solution that is then spun into one
solid fibre. Blending exposes the drug to harsh solvents, which can greatly decrease its
bioactivity. Additionally, blend electrospinning is expected to provide less control of the
release process as the drugs will be distributed randomly throughout the cross-section of
the fibre. Conversely, coaxial electrospinning has been demonstrated to have tuneable
release kinetics, allowing for regulation of the release kinetics [49]. Furthermore, coaxial
electrospinning can preserve the biological activity of drugs due to mild reaction
conditions [21]. Thus sensitive bioactive therapeutics, like growth factors, can be
successfully incorporated and released from nanofibrous scaffolds without a significant
loss in activity.
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Table 2.3 - Examples of Controlled Release from Electrospun Fibres
Shell
Polymer*
PCL-PEEP

Released Drug

Applications

References

Human Nerve GF

Nerve tissue regeneration

[75]

Metronidazole benzoate

Periodontal disease

[76]

Heparin

Vascular disease

[77]

PDGF-bb

Cardiovascular disease

[49]

Ketoprofen

Rheumatic disease

[22]

Plasmid DNA

RNA interfere

[73]

Paclitaxel

Antitumor agent

[74]

Basic Fibroblast GF

Ligament/tendon
regeneration

[78]

Cefazolin

Wound healing

[79]

PCL

PLLA

PLGA

*PLLA - Poly(L-lactic acid), PCL-PEEP - PCL-co- Poly(ethyl ethylene phosphate)
2.4.2 Release Kinetics
The most common empirical model used to illustrate drug release is the Power Law
developed by Ritger and Peppas (Eq. 2.1) [80]:
— = ktn
Moo

(2.1)

Where Mt is the amount of drug released at time t, M® is the total amount of drug loaded,
n is the diffusional exponent and k is a constant that accounts for characteristics relating
to the geometry of the device as defined by Ritger and Peppas [80]. The value of the
diffusional exponent n is indicative of the transport mechanism the system is exhibiting
(Table 2.4). The Power Law can be viewed as a simplification of overlapping
mechanisms of drug transport: Fickian diffusion and Zero-order kinetics.
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Table 2.4 - Power Law Variables n and k Defined in Relationship to Geometry [80]
Diffusion Exponent, n
Geometry
Diffusion
Anomalous
Zero Order

Thin Slab
0.50
0.50 < n < 1.0

Cylinder
0.45
0.45 < n < 1.0

1.0

1.0

Sphere
0.43
0.43 < n < 1.0
1.0

Kinetic Constant, k
4(D/ti/2)1/2

4(D/7ta2)1/2

6(D/;ta2)1/2

*1 is the thickness o1'the slab and a is the rac ius of the cylinder/sphere
Most controlled release systems are based on diffusion, the migration of a drug from one
point to another, and can be either reservoir or matrix based systems. Reservoir systems
encapsulate the drug within a polymer layer and are governed by Fick’s First Law of
Diffusion (Eq. 2.2) [71]:

J = ~ DI

<2-2>

Where J is the flux, dC/dx is concentration gradient and D is diffusion coefficient. The
release rate is determined by the ability of the drug to diffuse through the polymer
coating and is independent of the initial drug concentration and time. Drug release from
reservoirs is mainly influenced by the thickness of the outer polymer layer and the
diffusion coefficient, so it follows zero-order kinetics [81].

Matrix DDS have the drug dissolved or dispersed within the polymer matrix. Although
the rate determining step is diffusion through the polymer, matrix systems are dependent
on the initial concentration of the drug, Co, and the drug’s solubility, Cs- In dissolved
systems (Co < Cs), the release rate decreases with time and follows Fick’s Second Law of
Diffusion (Eq. 2.3):

— —n —
St

Sx2

(2-3)
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Where C is the concentration, D is the diffusion coefficient and x is the one dimensional
direction of diffusion. This has been adapted by Ritger and Peppas for geometries of thin
slabs (Eq. 2.4a, Eq. 2.4b) and cylinders (Eq. 2.5) [80]:
When:
A1t

(2.4a)

0 < TT“ < 0.6
Moo

When:

0.4

Mt
< — — <

M,00

(2.4b)

1.0

When:
0

<

Mt
—

-

Moo

<

(2.5)

0.2

Where Mt is the amount of drug released at time t, M* is the total amount of drug loaded,
D is the diffusion coefficient, 1 is the thickness of the slab and a is the radius of the
cylinder. In dispersed systems (Co > Cs), the rate is limited by the ability of the drug to
dissolve in the matrix. This type of release has been modelled by Higuchi (Eq. 2.6) [82]:
=

y/D(2c0 -

cs)cs t

(2 .6 )

Where Mt is the cumulative amount of drug released at time t, A is the surface area, D is
the diffusion coefficient, Co is the initial drug concentration, and Cs is the solubility of
drug in polymer. This model makes several assumptions [71, 82]: (i) that Co » Cs, (ii)
swelling is negligible, (iii) perfect sink conditions are maintained, (iv) constant drug
diffusivity, and (v) one-dimensional diffusion only, i.e. edge effects are negligible.

Drug delivery from matrix systems depends on the solubility of the drug in the polymer;
this becomes a problem in cases involving water-soluble drugs (like proteins) with
hydrophobic polymers. In these cases, the drugs are dispersed throughout the polymer
and can only dissolve when system is placed in an aqueous media. Drugs do not diffuse
through the polymer, rather they are released through the matrix’s water-filled pores [81].
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2.5 Material Selection
2.5.1 Polymers
2.5.1.1 Poly(caprolactone)
Poly(caprolactone) (PCL) is biocompatible, biodegradable polyester, and is prepared by
polymerization via ring opening of e-caprolactone as can be seen in Figure 2.11.

Figure 2.11: Reaction mechanism illustrating ring opening polymerization of ecaprolactone into linear poly(caprolactone).
PCL can be degraded under physiological conditions through hydrolysis of its ester
linkages, and because of this property, it is an attractive material for various uses
biomedical applications. Currently there are several FDA-approved medical implants
with PCL components, including medical sutures, drug delivery devices and implant
coatings [83]. Furthermore, unlike other common biodegradable polymers, when PCL
degrades its by-products are neutral and do not cause a change in the pH of the local
environment [54].

2.5.1.2 Poly(ethylene glycol)
Poly(ethylene glycol) (PEG) is a flexible, water-soluble polyether that has a low toxicity
and is used in a variety of medical applications (Figure 2.12). PEG has been
demonstrated to act as a porogen when incorporated into the polymer matrix of DDS, and
has the ability to modulate the release kinetics [84-85].

Figure 2.12: Chemical structure of poly(ethylene glycol).
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2.5.1.3 Type I Collagen
Collagen is the most abundant protein in the body, with superior properties in terms of
mechanical strength, thermal stability and wound healing [86]. It is a major component of
skin, bone and muscle tissues, and several diseases have been linked to improper collagen
production [87]. The unique physical properties associated with collagen are correlated to
its hierarchical fibrillar structure (Figure 2.13).
Polypeptide
Chains

vwv

Tropocollagen

Figure 2.13: Schematic diagram illustrating collagen’s hierarchical structure (Adapted
from [88]).
Type I collagen is composed to two ai and one aj left-handed coiled polypeptide chains
with the characteristic “Gly-X-Y” amino acid sequence. Glycine accounts for a third of
all amino acid residues in collagen, and the X and Y residues are random amino acids but
most commonly are proline or hydroxyproline residues [89]. These three polypeptide
chains combine to create a single tropocollagen (TC) molecule, with a length of
approximately 300 nm [88]. TC is composed of three chains coiled into a right-handed
coil, opposite the native direction of the individual chains, and has a tertiary structure
called a coiled-coil [86]. Collagen fibrils are composed of staggered TC groups with gaps
approximately 67 nm, which gives collagen its characteristic banding pattern (Figure
2.14). Recently, one group was able to electrospin human placental collagen nanofibres
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that exhibited the typical 67 nm banding pattern [90]. The larger collagen fibrils are held
together by both intra and inter-strand hydrogen bonding and by strand-strand
crosslinking. Finally, the collagen micro-fibrils join together to create larger structures in
various bone, muscle and skin tissues [86].

Collagen Microfibril

immm mmm mm

mmmm
mmm
mm
mm mmm. mmm m
Figure 2.14: Schematic diagram demonstrating how the 67 nm banding pattern on native
collagen appears.
Collagen has been an attractive resource for biomaterials research because it is
biocompatible, non-immunogenic and has favourable mechanical properties. In
particular, electrospinning of collagen is being considered for cardiovascular TE because
the resulting fibres can most closely mimic the native ECM [91]. Recently, the
mechanical properties of electrospun type I collagen nanofibres has been explored, with
results within the range of native tissues [92-93].

2.5.2 Growth Factors
Growth factors are a class of polypeptides that influence cell behaviours like locomotion,
proliferation and differentiation [2, 52, 94, 95]. The effects are often concentration
gradient dependent; for example cell migration is induced in the direction of the
concentration gradient [64]. Incorporation of growth factors is critical to the success of
tissue engineered constructs because they can direct tissue development and remodelling
[96]. Unfortunately, growth factors have a short lifetime in-vivo so controlled release of
these substances would be ideal for sustaining long-term stimulation [2, 4]. Furthermore,
growth factors improve communication between the cells, artificial matrix and
surrounding environment, providing necessary signals for the integration of developing
tissue [4, 96]. Some examples of growth factors used in current TE initiatives are
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transforming growth factor beta, fibroblast growth factor, insulin-like growth factor and
platelet derived growth factor [2, 94, 96].

2.5.2.1 Platelet Derived Growth Factor (PDGF)
Of particular interest to the present project is the growth factor platelet derived growth
factor (PDGF). It is a 30 kDa protein composed of two subunits, a or b, joined by
disulfide linkages [97]. There are two different PDGF receptors, a or p, that respond to a
specific isoforms (aa and bb or ab respectively). Upon binding, the PDGF receptor
undergoes auto-phosphorylation on tyrosine residues which activates a cascade that
ultimately leads to increased gene expression in the nucleus [98]. The PDGF-bb isoform
was chosen for this work because it has more powerful inductive effects because of its
ability to active both a and p receptors [99]. PDGF-bb plays various roles in wound
healing, tissue regeneration and tissue repair by recruiting cells and encouraging them to
proliferate inside the wound [97, 99]. Furthermore, when cells are exposed to a PDGF
concentration gradient, it induces them to migrate down the gradient [100].
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Chapter 3: Materials and Methods
3.1 Materials
The following were purchased from Sigma Aldrich, Oakville, ON, Canada:
-

Poly (e-Caprolactone) (PCL) (440744, Molecular Weight of 80 kDa)

-

Trifluoroethanol (TFE) (T63002, 2,2,2-TFE Reagent Plus®)

-

Type I Collagen (C7661, Collagen, Type I; from Rat Tail)

-

Hexafluoroisopropanol (HFIP) (105228, 1,1,1,3,3,3-hexafluoroisopropanol)

-

Bovine Serum Albumin-Fluorescein Isothiocyanate (A9771, BSA-FITC)

-

Poly (Ethylene Glycol) (309028, 10 kDa)

-

Sodium Phosphate Dibasic Heptahydrate (431478, Na2HP04 • 7H2O)

-

Tween® 20 (93773, Tween® 20)

-

Potassium Chloride (P9333, KC1)

-

Glycine (241261)

-

Sodium Dodecyl Sulphate (L4390, SDS)

-

Ponceau S (P3504)

-

Tris(hydroxymethyl)aminomethane (T1503, TRIS Base)

-

Medium M l99 (M4530)

-

Formalin solution, neutral buffered, 10% (HT501128)

The following were purchased from R&D Systems, Minneapolis, MN, USA:
-

Recombinant Human PDGF-BB (220-BB, > 97%)

-

Human PDGF-BB DuoSet ELISA Development kit (DY220)

-

ELISA Substrate Reagent Pack (DY999)

The following were purchased from Caledon Laboratories, Georgetown, ON, Canada:
-

Sodium Chloride (7560-1, NaCl)

-

Potassium Phosphate Monobasic (6660-1, > 99%)

-

Ethanol (1500-1, >95%)

-

Sulphuric Acid (8825-1, > 95%)

-

Acetic Acid (100-8-60, > 99%)
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The following were purchased from Bio-Rad Laboratories (Canada) Ltd, Mississauga,
ON, Canada:
-

Protein Assay Dye Reagent Concentrate (500-0006)

-

30% Acrylamide/Bis Solution (161-0154)

-

Tetramethylethylenedi amine (TEMED) (161-0801)

-

Ammonium Persulfate (APS) (161 -0700)

-

Bromophenol Blue ( 161 -0404)

-

Sodium Dodecyl Sulfate (SDS) (161-0301)

-

Thick Blot Paper ( 170-3966)

The following were purchased from Invitrogen Canada Inc, Burlington, ON, Canada:
-

Albumin From Bovine Serum, Alexa Fluor® 594 conjugate (Cat# A 13101 )

-

Protein Assay Dye Reagent Concentrate (500-0006)

-

Novex® Sharp Pre-stained Protein Standard (LC5800)

-

Hoechst 33342 (HI399)

-

Hanks' Balanced Salt Solution (HBSS, 14175-103)

-

Dulbecco’s Modified Eagle Medium (DMEM, 31053-028)

-

Fetal Bovine Serum (FBS, 10091-155)

-

Penicillin-Streptomycin (P/S, 15140-163)

-

Amphotericin B (Fungizone®, 15290-018)

Additional Reagents:
-

Fisher Bioreagents Bovine Serum Albumin (BSA) (Fisher Scientific Company,
Ottawa, ON, Canada, Cat# BP 1605100)

-

Donkey Anti-Goat IgG- Horseradish Peroxidase Conjugated Secondary Antibody
(Santa Cruz Biotechnology Inc., Santa Cruz, CA. Cat # SC-2033)

-

Goat Anti-Rat Type I Collagen Alpha 1 Primary Antibody (Santa Cruz
Biotechnology Inc., Santa Cruz, CA. Cat # SC-25974)

-

Thermo Scientific Pierce SuperSignal West Pico Chemiluminescent Substrate
(Fisher Scientific Company, Ottawa, ON, Canada, Cat# PI-34076)

-

(BSA) (Fisher Scientific Company, Ottawa, ON, Canada, Cat# 9048-46-8)
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-

VECTASHIELD® Mounting Medium (Vector Laboratories Inc, Burlingame, CA,
United States. Cat# H-1000)

-

Complete, Mini, EDTA-free Protease Inhibitor Cocktail Tablets (Roche
Diagnostics Canada, Laval, Quebec. Cat#l 1836170001)

-

Instant Powdered Milk, Carnation brand

3.2 Solutions
3.2.1 Polymer Shell Solutions
Shell solutions of 12 wt% PCL and 5 wt% type I collagen were prepared as follows. PCL
solutions were made by dissolving 1.2 g of PCL in 10 mL of TFE for 6 hours at room
temperature. Type I collagen solutions were prepared by adding 94.2 mg of type I
collagen from rat tail to 1 mL of HFIP, and vortexing to dissolve the collagen.

3.2.2 Protein Core Solutions
3.2.2.1 Bovine Serum Albumin
Previous work demonstrated that core solutions with BSA concentrations of 10 mg/mL
were optimal for controlled release experiments [101]. In brief, 100 mg of BSA was
dissolved in 10 mL of double distilled water and mixed thoroughly, to obtain a final
concentration of 10 mg/mL. PEG, molecular weight of 10 kDa, was added to the core
solution to provide stability and prevent mixing during the electrospinning process. PEG
was dissolved into the BSA core solution to yield a final concentration of 200 mg/mL.

In addition, fluorescently labelled albumin proteins were used in core solutions for both
PCL and type I collagen fibres for confocal imaging. For PCL and type I collagen fibres,
BSA-FITC (ex. 495 nm, em. 520 nm) and BSA-Alexa Fluor 594 (ex. 590 nm, em. 620
nm) were used respectively. For these experiments, BSA concentrations of 10 pg/mL
were determined to be optimal. For PCL scaffolds, BSA-FITC was dissolved in 1 mL of
double distilled water and mixed thoroughly, to obtain a final concentration of 10 pg/mL.
PEG was dissolved into the BSA core solution to yield a final concentration of 200
mg/mL. For collagen samples, PEG was dissolved into 80-90 % ethanol to yield a final
concentration of 200 mg/mL. Next, BSA-FITC or BSA-Alexa Fluor 594 was slowly
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dissolved in 1 mL of the PEG-ethanol solution, to obtain a final concentration of 10
pg/mL. Solutions were wrapped in tin foil and stored at 4 °C to preserve fluorescence.

3.2.2.2 Growth Factor Solutions
Recombinant human PDGF-bb was reconstituted using 4 mM hydrochloric acid
containing 0.1 % BSA.

Once fully dissolved, the solution was diluted with PBS

containing 1 % BSA to yield a final concentration of 10-1000 pg/mL. Finally, PEG was
added to this final solution at a concentration at 120 mg/mL

3.2.3 Buffers and ELISA Solutions
All buffers and solutions were prepared according to protocols found in Appendix A.

3.3 Methods
3.3.1 Electrospinning Setup
3.3.1.1 Single Pump

A single syringe pump (KD Scientific Inc.) was used to create solid PCL and collagen
fibres. An electric field of 10 - 25 kV was created by connecting a voltage source
(Glassman High Voltage Inc.) to the tip of the metal 30 gauge needle and a custom
designed stationary metal collector, as shown in Figure 3.1.

Figure 3.1: Custom designed electrospinning setup.
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3.3.1.2 Coaxial Electrospinning
Coaxial electrospinning was performed as previously established [101]. Two solutions
were fed concentrically into a single metal needle tip using a capillary tube system. A
flexible silica capillary tube, inner diameter of 250 pm, was threaded into the plastic
syringe into a 20-gauge needle until it was flush with the metallic needle tip. The flow
rates of each solution were independently controlled using a dual syringe pump (Model
33, Harvard Apparatus). The voltage source and metal collector were the same as those
mentioned previously.

3.3.1.3 Parameters
Systematic trial and error was used to establish a standard set of variables which were
able to form continuous fibres for both solid and hollow fibres. The combinations of
variables that were used to create fibres are summarized in Table 3.1.
Table 3.1 - Electrospinning Parameters for Solid and Hollow Fibres
Sample

Flow Rates*
(ml/hr)

Distance
(cm)

Voltage
(kV)

12 wt% PCL

0.1-0.3

15-18

13-15

5 wt% Collagen

0.15-0.25

18-20

10-12

OFR: 0.30
IFR: 0.10

15-18

12-15

OFR: 0.30
IFR: 0.10

15-18

13-15

OFR: 0.30
IFR: 0.08

15-18

13-15

OFR: 0.18
IFR: 0.06

18-20

9-11

Solid

Core-Shell

12 wt% PCL
10 pg/ml BSA-FITC + 20
wt% PEG
12 wt%PCL
10 mg/ml BSA + 20 wt%
PEG
12 wt%PCL
1 mg/ml PDGF + 20 wt%
PEG
5 wt% Collagen
10 pg/ml BSA-FITC/Alexa
Fluor 594 + 20 wt% PEG

*O FR is the outer flow rate o f the polym er shell and IFR is the inner flow rate o f the core solution

3.3.2 Isolation of Type I Collagen from Rat Tails
The procedure for the isolation of type I collagen from rat tails is detailed in Appendix B.
In brief, frozen rat tails were thawed in 70% ethanol, dissected to expose the white
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collagen fibres, which are then removed and placed in a separate sterile dish. Fibres are
washed in 70% ethanol for 30 minutes, dried in a sterile Petri dish and left overnight to be
sterilized under UV light. Collagen fibres are then dissolved in an acetic acid solution (1
mL of concentrated acetic acid in 1 L of distilled water) in cold room (at 4 °C) over 4-7
days. The solution is centrifuged at 11, 000 rpm (10, 000 g) for 2 hours and the
supernatant was collected. Protein concentration was measured using the Sircol Collagen
Assay and found to be 1.8 mg/ml. Collagen solution was stored at this point at 4 °C or
frozen overnight at -20 °C and lyophilized for 1-2 days to obtain dry collagen powder.

3.3.3 Isolation of Porcine Radial Artery Cells
RAC isolation was performed as previously described and is detailed in Appendix C
[102]. In brief, radial arteries were dissected out of porcine forelimbs in sterile lab
conditions. The porcine radial arteries were minced and digested in a 0.08% collagenase,
0.25pg/mL Amphotericin B, and 1% Penicillin/Streptomycin solution for 24 hours at
37°C with constant stirring. The solution was then centrifuged for 5 minutes at 1100 rpm
and the supernatant was discarded. Tissue pieces from the pellet were plated onto 100
mm dishes and cells were removed after substantial cellular outgrowth.

3.4 Characterization
3.4.1 Microscopy
3.4.1.1 Scanning Electron Microscopy (SEM)
A Leo 1530 scanning electron microscope was used to obtain images of solid fibres. An
accelerating voltage of 2 kV was used because it was a sufficient amount to prevent
damage to the samples while still generating high resolution images. The surface
morphology, diameter and diameter distribution were characterized using SEM images.

3.4.1.2 Transmission Electron Microscopy (TEM)
A Philips CM 10 transmission electron microscope was used to obtain images of core
shell collagen fibres. Collagen core-shell fibres were spun directly onto a TEM grid and
an accelerating voltage of 2 kV was used. The core and fibre diameters and diameter
distribution were characterized using TEM images.
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3.4.1.3 Laser Scanning Confocal Microscopy (LSCM)
A Carl Zeiss Laser Scanning Confocal Microscope (LSM-410) equipped with an
Argon/He/Ne laser and a Zeiss LSM 510 inverted microscope was used to image cell
proliferation and encapsulated fluorescent proteins. DNA binding fluorescent dye
Hoescht 33342 has excitation and emission wavelengths of 350 nm and 461 nm,
respectively. The excitation and emission wavelengths of BSA-FITC are 488nm and
568nm, and Alexa Fluor 594 are 590 nm and 622 nm, respectively.

3.4.2 In-vitro Protein Release
3.4.2.1 Theoretical Loading Calculations
To determine the theoretical amount of protein loaded into the scaffolds, a mass balance
approach was used; for detailed calculations see Appendix D. The ratio of the expected
masses was used to determine what percentage of the scaffold mass could be attributed to
the various components (like PCL, PEG, BSA, etc.).

3.4.2.2 Bradford Assay
The Bradford Assay developed by Bradford was used to measure protein concentration
and the standard protocol is detailed in Appendix E [103]. In brief, the absorbance of
Coomassie Brilliant Blue dye at 595 nm can be related to protein concentration according
to Beer’s Law. A Tecan Infinite® 200 PRO multimode reader was used to measure the
absorbance at 595 nm.

3.4.2.3 ELISA
A sandwich ELISA was performed using Elisa DuoSet Development kits purchased from
R&D Systems. The detailed protocol is located in Appendix F. Briefly a 96-well plate is
coated with the primary detection agent over night, blocked with BSA then incubated
with serially diluted samples for 2 hours. After rinsing, samples were incubated with a
secondary antibody conjugated with horseradish peroxidase. Finally the samples are
incubated with a 50:50 mixture of hydrogen peroxide and 3,3’,5,5’-Tetramethylbenzidine
for 20 minutes. The reaction is stopped with 2 N sulphuric acid and the absorbance is
measured at 450 nm and 570 nm using a Tecan Infinite® 200 PRO multimode reader.
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3.4.2.4 Protocol
Protein release was evaluated using core-shell scaffolds that were approximately 1 cm ,
incubated in phosphate buffered saline (PBS) at 37 °C for 10 days. Samples were
submerged in 500 pL of PBS that was collected at various time points and replaced with
fresh PBS kept at 37 °C. Samples were analyzed immediately or stored at 4 °C.

3.4.3 Cell Staining and Counting
Porcine RACs were used to measure cell viability on the PCL core-shell scaffolds. RACs
were used because they have been established to be a viable surrogate cell source for
aortic valve tissue regeneration [104]. Fibres were electrospun directly onto silicon
wafers cut into 0.5 cm2 squares, 15 000 cells were seeded and cultured for 24, 48 and 72
hours. At each time point, samples were fixed in a 10 % formalin solution for 30 minutes
and mounted using a 1:100 mixture of Hoescht 33342 dye and Vectashield mounting
media. Cell nuclei were visualized using LSCM.

3.4.4 Collagen Purification
3.4.4.1 Infrared Spectroscopy
Infrared data was collected using a Bruker Vector 22 Fourier Transformed Infrared
(FTIR) spectrometer plus an Attenuated Total Reflectance (ATR) attachment (Pike
Technologies Inc., Madison, WI) with a diamond crystal. Spectra were obtained in
transmittance mode with 32 scans with a resolution of 4 c m 1.

3.4.4.2 SDS-PAGE and Western Blotting
The detailed protocols are located in Appendix G. In brief, 500 pg of Type I Collagen
from Rat Tail from Sigma-Aldrich (C7661) and our isolated samples were dissolved in
400 pi lysis buffer. Samples were homogenized with tissue homogenizer (Ultra Turrax
T25 homogenizer, IKA Laboratory Equipment) for 2-3 minutes each and then sonicated
on ice (Model 500 Dismembrator, Fisher Scientific) for 20 seconds total (in pulses of 5
seconds on 2 seconds off) at 30% amplitude. Finally, samples were heated to 95 °C for 3
minutes to solubilise collagen.
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Samples, along with Novex® Sharp Pre-stained Protein Standard, were loaded into a 6%
acrylamide gel and run at 120 V for 90 minutes. The samples were then transferred to a
nitrocellulose membrane at 75 V for 90 minutes. The blot was incubated with the primary
antibody Goat Anti-Rat Type I Collagen Alpha 1 for 1 hour. After three washes, it was
incubated for 1 hour with the secondary antibody Donkey Anti-Goat IgG- Horseradish
Peroxidase Conjugated. Finally, the blot was incubated for 5 minutes with Super Signal
and imaged using a ChemiGenius 2 Bioimaging System from Syngene.

3.5 Statistics and Data Analysis
Statistical analysis was carried out using Microsoft Excel (Microsoft Corp.) or Sigma
Plot (Systat Software Inc). Data was analyzed by one-way analysis of variance
(ANOVA) or student’s t-test to determine significance between groups. In all
experiments p- values of less than 0.05 were considered significant.
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Chapter 4: Results and Discussion
The main objective of this work is to create core-shell nanofibres composed of type I
collagen with encapsulated growth factors, which can be used as a scaffold for heart
valve leaflet tissue regeneration. In order to achieve this goal, a well-established
biocompatible and biodegradable polymer, PCL, is used for the development of a method
for creating core-shell nanofibres. It is important to have this foundation such that a
detailed understanding of the coaxial electrospinning process and the mechanisms of
release from hollow fibres can be well understood. The incorporation of a model protein,
BSA, into the core of the PCL fibres is utilized to study and comprehend the underlying
release kinetics. Afterwards, PDGF can be incorporated into the PCL model fibre system
to evaluate its release. The BSA and PDGF containing scaffolds can have their in-vitro
performance compared to demonstrate successful release from the core and preservation
of PDGF activity. Finally, core-shell fibres consisting of type I collagen as the polymer
shell and BSA and PDGF in the core can be prepared and their release kinetics studied
for use as scaffold materials for heart valve leaflet tissue regeneration.

4.1 Preparation o f Core-shell PCL/BSA Fibres
The initial portion of this work involved learning how to create core-shell nanofibres via
coaxial electrospinning. Preliminary parameters were: 12 wt% PCL polymer shell
solution, 20 wt% PEG with 10 pg/mL BSA-FITC core solution, applied voltage between
12-20 kV and distances between the syringe needle tip and the collector electrode of 12
20 cm. From previous work in our laboratory, outer and inner flow rate combinations of
0.6 ml/hr-0.2ml/hr, and 0.3 ml/hr-O.lml/hr were selected because they produced good
quality fibres with a narrow diameter distribution [101]. It is important to note that the
outer to inner solution flow rates (1:3) is consistent with the rates reported in the
literature [21, 49]. The initial trials using the faster flow rates (OFR 0.6 ml/hr, INF 0.2
ml/hr) tended to yield larger fibres with beading, so all further experiments were
completed using the slower flow rates of 0.3 ml/hr and 0.1 ml/hr for the shell and core
solutions respectively. Samples prepared using optimized preparation conditions were
imaged using LSCM to verify the encapsulation of the fluorescently tagged protein.
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Results are shown in Figure 4.1 and Figure 4.2, and the fibres exhibit the expected green
fluorescence from encapsulated BSA-FITC protein.

600 800 1000 1200 1400
Fibre Diameter (nm)
Figure 4.1: Confocal image of PCL/BSA-FITC nanofibres and fibre diameter
distribution, with an average fibre diameter was 1069 ± 388 nm (n = 175).
The average fibre diameter of the PCL-BSA core-shell fibres was 1069 ± 388 nm, which
is comparable with the 0.8-5.5 pm range of demonstrated in literature [85, 105]. It is
important to note that PCL does not fluoresce under confocal microscopy imaging
conditions therefore all fluorescence seen is attributed to BSA-FITC [84]. Another
important observation is the fluorescence appears in the form of small green beads that
are unconnected (Figure 4.2a) indicating that the entire fibre itself is not fluorescing. This
suggests that there is no significant mixing between the core and shell solutions in the
electrospinning process resulting in a distinct core-shell structure. These results based on
PCL-BSA core shell fibres establish the necessary foundation to reach the main goal of
this work, which is the localized delivery of bioactive proteins via hollow type I collagen
nanofibres.
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Figure 4.2: Confocal images of PCL/BSA-FITC nanofibres illustrating the difference
between fibres when beading of the core solution does (a) and does not (b) occur.

4.2 Protein Release from PCL-BSA Fibres
4.2.1 Release Profile of BSA from Core-Shell PCL Fibres
Based on the results in section 4.1, core-shell fibres consisting of PCL-BSA were
prepared in the form of scaffolds. These scaffolds had an average mass of 3.6 ± 0.3 mg
and contained an average of 62.7 ± 5.7 pg of BSA. Following the procedure outlined in
section 3.4.2, the release profile of BSA was determined (Figure 4.3). Over a period of
10 days samples were able to deliver 22.2 ± 1.4 pg of BSA, which is 35.3 ± 2.2 % of
theoretically loaded protein. It was found that protein release from PCL-BSA scaffolds
demonstrated a Fickian diffusion based profile, with calculated variables and correlation
constants summarized in Table 4.1. Details are discussed below.

Figure 4.3: Release profile of BSA from PCL core-shell scaffolds. Approximately 35.3 ±
2.2 % of theoretically loaded protein was released at 37 °C over 10 days.
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4.2.2 Protein Release Procedure Discussion
For release experiments, the Bradford assay was used to quantify the amount of protein
released at each time point. This method was chosen because it is well established in the
literature, has a high degree of sensitivity and can be modified to decrease the range of
detectable amounts of protein down to the micro gram scale (1-25 pg/mL), which was
needed for these experiments [106]. In addition, experimental conditions were modified
to increase assay sensitivity. These include increasing the concentration of BSA in the
core solution, decreasing the amount of buffer the samples were incubated in and
increasing the time between sample collections.
Other assays used for measuring microgram quantities of protein, like the Bicinchoninic
Acid (BCA) Microassay and Lowry Assay, have also been widely used in the literature;
however, a recent publication indicated that the presence of PEG in the fibres can
influence the precision of these assays [84]. In order to assess if PEG influenced the
accuracies of the Bradford assay, experiments were carried out using various
combinations of PEG and BSA and analyzed. In the end, it did not appear that the
concentration of PEG influenced the accuracy of the data over the range of BSA
concentrations used in the current set of experiments (Figure 4.4). There was only one
concentration of BSA (16 pg/mL) that was significantly different (p = 0.0158, using
paired t-test for comparing means) from the control (0 pg/mL PEG) and the sample (500
pg/mL PEG); however, points with BSA concentrations higher than 16 pg/mL with
varying concentrations of PEG did not differ significantly (p = 0.3648) (supplemental
data is located in Appendix H). It is also important to note that concentrations of BSA
and PEG do not reach the range that exhibited this difference during these experiments.

36

Figure 4.4: The influence of PEG on BSA absorbance was analyzed using Bradford
Assay by scanning several samples composed of the same amounts of BSA and varying
amounts of PEG. Only one data point showed a significant difference between samples
with and without PEG (p = 0.0158). Legend: Inc BSA-No PEG = 0-25 pg/mL BSA, 0
pg/mL PEG, Inc BSA-PEG 500 = 0-25 pg/mL BSA, 500 pg/mL PEG.
4.2.3 Protein Release Data Interpretation
Currently in the literature, very few studies have been published which analyze protein
release kinetics from electrospun core-shell nanofibres [75, 76, 84]. Controlled release
systems of well-defined macroscopic geometries have been thoroughly studied, but
translation of that knowledge to nanoscale structures has been limited. This is most likely
because, on the macroscopic scale nanocale delivery systems consist of many units of the
same geometry. As a result, it is hard to elucidate which is the best model for a delivery
system composed of nanoscale units. For example, the individual core-shell fibres have
been proposed to act as reservoirs because the outer polymer shell can act as a barrier to
control diffusion [84], However, the release profile exhibited by this data suggests that it
is not representative of the entire system. Reservoir systems generally follow zero order
kinetics, but this is not the case with release from core-shell nanofibres, which have been
demonstrated to be dependent on the initial protein concentration [76-77], Alternatively,
zero order release, similar to that of a reservoir, has been demonstrated from blended
electrospun samples [74].
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Another polymeric drug delivery model to consider is a matrix or monolithic system. In
matrix systems, the drug can be dissolved or dispersed; dispersed systems are typically
used to describe insoluble drugs and follow the Higuchi Model (Eq. 2.6). The Higuchi
model was considered for our data because the solvent evaporates during electrospinning,
ultimately leaving non-solubilised protein within the fibre core. As mentioned previously
in Chapter 2, there are several assumptions made in the Higuchi model, most of which
are not applicable to our system. The most important assumption in the Higuchi model is
that the initial drug concentration is much higher than its solubility. However, this is not
the case for the PCL-BSA system since the amount of BSA loaded into the samples was
relatively small (62.7 ± 5.7 pg) and BSA will readily dissolve in aqueous solutions. Thus,
the assumptions used in the Higuchi Model are not applicable to this system [82].

To model release from electrospun fibres, several studies assumed the system has a
cylindrical geometry and release was occurring via diffusion through the fibre wall. This
assumption allows the Power Law (Eq. 2.1) to be applied to our data and is shown in
Figure 4.5. The treatment of a nanofibrous mesh as the linear summation of all cylinders
in the matrix seems to be the most reasonable model for several reasons. The fibrous
mesh has an aspect ratio, which is defined as the ratio of the diameter to the length, closer
to an infinite cylinder rather than that of a thin slab. If the ideal case is assumed, with an
average fibre diameter of 1069 nm and average fibre length of 1 cm (as defined by the
scaffold dimensions), then the resulting aspect ratio is very large and, based on the Power
Law model, a value of n = 0.45 is expected [80], When the best fit to the empirical
Power Law was determined, the n and k values were found to be 0.39 and 1.83 x 10~3,
respectively, with a correlation coefficient of 0.995. The obtained n value is lower than
expected, so to gain a better understanding of the applicability of the Power Law to our
nanofibrous system, the data was fit to the cylinder model with n = 0.45 for comparison
'y

(Figure 4.5); the resulting k and R values are presented in Table 4.1.
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0.45

Figure 4.5: Comparison of BSA release from PCL scaffolds (■) to predicted diffusion
Power Law model for perfect cylinders, n = 0.45 (-), and best fit model, n = 0.39 (-).
Table 4.1 - Comparison of Power Law Variables n and k Derived from Release Data
Empirical Diffusion Models
Best Fit - Power Law (Eq. 2.1)

Perfect Cylinder Power Law (Eq. 2.1)

n

M,/Moo = ktn
0.39

M./1VL = kt° 45
0.45

k

1.83 x 10'3

0. 80 x 10‘3

D (cm V )
R2

1.88 x 1015
0.995

0.36 x 1015
0.983

Equation

The curves in Figure 4.5 compare the best fit model (n = 0.39) and the Power Law for
cylindrical geometries (n = 0.45). It can be seen that they are very similar demonstrating
that the cylindrical model is a plausible and quite reasonable method to describe protein
release from our scaffold. Alternatively, the data can be presented linearly where
cumulative protein release is plotted as a function of the time to the exponent n. The
plotted n values were set at 0.45 for the Power Law for perfect cylinders model and the
experimentally derived best fit, which in our case is 0.39. The curve is shown in Figure
4.6. This approach is equivalent to that used to derive the curves in Figure 4.5 and the
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obtained k values, the slope of the linear plots in Figure 4.6, are in good agreement with
each other.

Figure 4.6: Plot of cumulative release of BSA from PCL core-shell scaffolds as a
function of time to the exponent n. Samples were plotted with the best fit n = 0.39 (R2 =
0.958) and the cylindrical Power Law Model n = 0.45 (R2 = 0.903).
The fitting parameters in the Power Law can be used to estimate a diffusion coefficient,
D, for our system using the k value for cylinder geometries shown in Table 2.4. The
values for D from the best fit model (n = 0.39) and the cylindrical model (n = 0.45) are
summarized in Table 4.1. The diffusion coefficient for both approaches is over a 5-fold
I c

range between 0.36-1.88 xl0‘

o

cm/s. These values compare favourably to a typical

diffusion coefficient of ~10 15 cm2/s for proteins [107], Additionally, Eq. 2.5, diffusion
from a cylinder, was considered when selecting models for the protein release data, but
the data did not fit. However, this was expected because the model is only accurate for
first 20% of release, which is why the Power Law developed by Ritger and Peppas is
used because it more accurately describes our set of experimental data [80].

Release of BSA from within PCL fibres represents an interesting release system because
water-soluble drugs, like proteins, are not soluble in hydrophobic polymers.
Consequently, diffusion of BSA is most likely not occurring through PCL; rather release
is anticipated to occur via small pores created by the leaching of PEG, which was
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included in the core solution. It has been demonstrated that PEG, which is very
hydrophilic, will release very quickly from the hydrophobic matrix into the aqueous
media in an initial burst [49]. Furthermore, evidence of holes left in the PCL outer shell
has been confirmed via SEM images [105]. Thus, BSA is not expected to diffuse through
polymer phase but preferably diffuses through the media-filled porous network. In this
sense, these nanofibres can be considered like typical filtration membranes in which the
pores are too small for large molecules, like proteins, to pass through except by diffusion.
In other words, release from hollow electrospun fibres can be treated as diffusion from a
cylindrical matrix with rates dependent on initial protein concentration and concentration
gradient [81].

Protein or drug release from PCL core-shell fibres has been demonstrated in the
literature, and our data is similar to those release profiles [49, 75, 76, 84, 85, 105].
Previous studies demonstrate approximately 30-40 % release of theoretically loaded
protein in 10 days, which corroborates with our data of 35.3 ± 2.2 %. Of the few studies
that have applied the Power Law to their data, our experimentally derived n value is in
good agreement with the literature (n values of 0.36 - 0.43) [75, 76, 84]. An important
distinction between our data and these data is the absence or presence of PEG in the core
or shell solutions. As mentioned before, PEG is a porogen and can be used to modulate
the release kinetics. For example, studies have shown that the presence of PEG in the
polymer shell can increase the release rate compared to samples without PEG [105]. We
demonstrate that the presence of PEG in the core solution can also influence the release
rate, although not to the same extent as incorporating it into the polymer shell, and this
has been corroborated in the literature [84]. Thus, the inclusion of PEG within the core
solution during coaxial electrospinning can also be used to modulate the release of
proteins from hollow nanofibres. Since the rate of release of each bioactive molecule is
specific to its needs during tissue regeneration process, the range of control demonstrated
using out approach provides important compliments to methods that have been reported
in the literature.
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Deviations from the expected n value from the Power Law for cylinders can be attributed
to several factors. Polymeric matrix systems have been demonstrated to have some form
of burst in the initial stages of release [108]. The main contributors to burst release are
process variables, heterogeneity of the matrix and properties of the drug [109].
Imperfections or holes in the fibres are created or redistribution of the drug during solvent
evaporation can occur during the electrospinning process [110]. The properties of the
drug being released can also influence the release profile. For example, the drugs used in
some of the studies were much smaller in size than BSA, which can alter the diffusion
kinetics. It has also been shown that BSA has a tendency to redistribute to the shell
surface when the solvent evaporates during electrospinning [108]. Another factor to
consider is the distribution of the fibre diameters because fibres of different sizes could
potentially have different protein and/or PEG loading and consequently, alter the release
kinetics.

Controlled delivery of growth factors from TE scaffolds is important because growth
factors and their method of delivery play a critical role in the success of tissue
regeneration and remodelling. Being able to understand protein release from nanofibrous
scaffolds is significant because it presents a method of controlling the rate of tissue
development. For example, PDGF is a chemoattractant, meaning that cells will migrate
towards it [95, 99]. By releasing PGDF from within the scaffold into the surrounding
media, the concentration gradient will trigger the cells to migrate deep into the scaffold,
which is important because it will allow remodelling to occur in three dimensions.
Additionally, the generation of new tissues is a lengthy process, and by delivering
therapeutic growth factors over an extended period of time, the process can be sustained.
When extrapolated over 30 and 60 days, the cumulative release of protein from the PCLBSA scaffold would reach approximately 60 % and 80 % respectively, as estimated based
on a diffusion coefficient of ~10'

cm /s determined in our experiments. By initially

drawing cells deep into the scaffold and then maintaining them in a proliferative and
migratory state, growth factor delivering scaffolds present a better TE scaffolding
material because the majority of the tissue formed will be developed in-vitro and be able
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to integrate more easily upon implantation. The kinetic analysis presented would allow
for the design of bioactive scaffolds not only for AHV leaflet, but for TE in general.

4.3 Growth Factor Release from PCL-PDGF-BB Fibres
Controlled release of BSA from core-shell PCL nanofibres studied in section 4.2 was
used to demonstrate and develop an understanding of protein delivery in fibrous
scaffolds. This experiment creates an opportunity to develop a bioactive scaffold for
tissue engineering by releasing therapeutic proteins, like growth factors, from hollow
nanofibres. One of the growth factor that is essential for TE is PDGF-bb, which has been
demonstrated to stimulate cell proliferation and migration against its concentration
gradient [95, 99].

It is crucial that a reliable and sensitive process is developed to

quantify the amount of growth factor released from the fibres. One such method is an
ELISA, which can accurately measure growth factor concentrations from 100-2000
pg/ml.

The first step in the growth factor trials was to develop an ELISA protocol and validate it
against the PDGF-bb in the core solution. Preliminary tests showed the concentration of
PDGF-bb in the core solution was 40-50% less than expected (all ELISA data can be
seen in Appendix I), suggesting an error in the standard or protein loss in the core
solution. The standard was re-examined and was found to be accurate, so the PDGF-bb
core solution was re-evaluated. After a great deal of troubleshooting, the original growth
factor was identified as the source of error, and upon using an alternative resource, the
accuracy of the assay improved.

Upon optimization of the ELISA, the fabrication core-shell nanofibres containing PDGFbb was attempted. However, while preparing control core-shell samples (fibres without
PDGF-bb) it became apparent that the humidity was influencing the coaxial
electrospinning process. In the time at which these samples were being prepared, the
relative humidity of the surrounding environment had increased. Increases in humidity
cause problems during coaxial electrospinning because increases in the water content in
the air prevented the water in the core solution from evaporating during electrospinning.
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Samples prepared during this time were composed of wet, beaded and/or woven fibres.
To overcome the effect of humidity, the flow rate of the core solution was decreased from
0.1 ml/hr to 0.05 ml/hr in increments 0.01 ml/hr, but smooth, dry fibres could not be
produced. Due to time constraints, these experiments could not be explored further;
however, some potential solutions include decreasing the water content of the core
solution by adding more PEG, or to creating an enclosed environment where the moisture
content can be controlled.

4.4 In-vitro Studies
Cell culture studies need to be performed on potential TE scaffolds because they need to
be compatible with cells and capable of sustaining cell growth. In this experiment porcine
RACs, which are a combination of myofibroblasts and smooth muscle cells, were used as
a cell source for in-vitro studies. RACs were chosen because they have been established
as a viable surrogate cell source for aortic valve tissue regeneration [102, 104], Initially,
in-vitro studies used a Sklar Tru-Punch biopsy punch to create circular scaffolds with a
diameter of 0.5 cm from PCL-BSA fibres spun onto tinfoil (Figure 4.7a); however
several problems were associated with this type of scaffold support. Mainly, the scaffolds
would float around in the media and did not provide proper anchorage for the cells.
Additionally, the scaffold would peel off the tinfoil, leading to a further decrease in
support and affected the reproducibility of the data.

Figure 4.7: Comparison of three types of cell culture supports bare and with fibrous
scaffold attached (from left to right): biopsy punch, bioreactor clamps and silicon wafers.
To overcome this, use of bioreactor clamps and silicon wafers were suggested. The
square bioreactor clamps create a scaffold area of 1 cm2 (Figure 4.7b), while the silicon
wafers were cut into 0.5 cm2 squares (Figure 4.7c); both of these offered enough support
to prevent the scaffolds from floating freely. The clamps were effective supports, but
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there were various associated problems with contamination and microscopy staining. The
silicon wafers provided the best support and samples were easily stained. Unfortunately,
no PDGF containing scaffolds were able to be produced because of problems associated
with the generation of PCL-PDGF scaffolds. The control samples were prepared to
develop a standard staining procedure in anticipation for comparison to PDGF-bb
containing PCL hollow scaffolds; this data was collected and is presented in Figure 4.8.
PCL-BSA scaffolds were able to sustain cell growth over three days, but no definitive
conclusions can be drawn from this data due to the lack of a suitable comparison.

4.5 Isolation and Purification o f Type I Collagen from Rat Tails
Previous work has demonstrated that type I collagen isolated from rat tails is superior to
that from calf skin because it creates non-woven fibres with smaller diameters and
narrow diameters distributions [111]. Recently, the quality of commercial sources of type
I collagen has been questioned, and thus a method was developed to produce and purify
collagen independently [112]. In these experiments, type I collagen was produced and
purified from rat tails. Results were compared to a commercially available product from
Sigma Aldrich (C7661).

Following the procedure outlined in section 3.4.4.2, solid collagen was successfully
isolated from rat tails and characterized by FTIR and western blotting. The FTIR spectra
of both Sigma and purified collagen samples are in agreement (Figure 4.9) and the
prominent peaks present in both samples are summarized in Table 4.2. Notable peaks
include the strong amide I and II bands, absorbing around 1650 cm'1, due to the presence
of peptide bonds along the polymer backbone and a sharp amide III peak around 1236
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cm' due to the large glycine content (increased CH2 wagging). All subsequent collagen
samples were compared to these spectra as standards to minimize batch to batch
variability and can be seen in Appendix J.
1
0.95

09
0.85
0.8

oc<u
(V
ag

M
C

0.75

£
*-

0.7

0.65
0.6

3900

3400

2900

2400

1900

1400

900

W avenum ber (cm )

-----Collagen from Rat Tails -----Sigma Collagen

Figure 4.9: FTIR spectra comparing the transmittance of rat tail collagen purchased from
Sigma-Aldrich to our purified collagen samples.
Table 4.2 - Summary of FTIR Peaks for Type I Collagen [113-115]
Expected Value (cm )

Observed Values* (cm )

Vibrational Source

N-H Stretching (Amide A)
Amide I, C=0 stretching vibrations
Amide II, N-H bending vibrations
1530-1560
1540,1546
C
with C-N Stretching
Amide III, C-CH2stretch or CH2
1250-1300
1234, 1236
D
wagging
1204-1280
C-O stretching
1031,1061, 1082
1031, 1081
E
Amide B (Amide II over tone)
3067-3077
3077
F
*Observed values are for Sigma and purified samples respectively
A
B

3300-3330
1650-1660

3307, 3311
1633, 1650

Although the FTIR data was in good agreement with the literature, the purity needed to
be examined more closely therefore a western blot was performed. A Western blot will
be more sensitive because it can detect specific proteins by using antibodies. To perform
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the blot, samples must be solubilised and separated by gel electrophoresis. Initial attempts
to dissolve collagen in buffer were unsuccessful; however, the use of a tissue
homogenizer, which uses mechanical force to break protein into smaller sized fragments,
was able to successfully dissolve all collagen. Samples were loaded onto a 6 %
polyacrylamide gel because lower acrylamide content is needed to resolve protein bands
over 100 kDa (molecular weight of collagen components is between 90-250 kDa); also,
blotting transfer time was increased to allow sufficient time for the large components to
migrate out of the gel.

The blot was stained with Ponceau S (Figure 4.10a) to visualize all protein bands present.
The first lane is a protein molecular weight marker used to approximate the size of the
other bands present on the blot. Four bands were identified in the sample lanes with
molecular weights around 260 kDa, 240 kDa, 140 kDa and 120 kDa. The stain was
removed and the blot probed with type I collagen alpha 1 antibodies; the alpha 1 subunit
was selected because type I collagen has a higher portion of alpha 1 subunits, and it
would be easier to detect. The initial blot did not show any bands responding to collagen,
so it was stripped and reprobed with a new secondary antibody which yielded bands at
the 120-140 kDa range (Figure 4.10b).

Type I collagen is composed of three polypeptide chains: two alpha-1 chains and a single
alpha-2 chain, both with molecular weights around 70-100 kDa.

Also, collagen

polypeptide chains have procollagen precursors with higher molecular weights around
150-210 kDa. The stained blot revealed the same banding pattern in the purified and
Sigma samples. There were two groups of bands, one set with molecular weights around
240-260 kDa (A) and another around 120-140 kDa (B), and indicated that the purified
and Sigma samples contained few containments. When probed with alpha-1 collagen
antibodies only the B bands were visualized. This was expected because collagen is
composed of several polypeptide chains, so not all bands would correspond to alpha-1
subunits. In addition, the other protein bands could represent other proteins, like the
alpha-2 subunits and its procollagen precursor. The B bands located at 120 and 140 kDa
correspond to alpha-1 subunits and alpha-1 procollagen respectively. The double banding
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pattern occurs because of the presence of the procollagens and has been demonstrated in
the literature [116]. The larger A bands are most likely fragments of collagen that did not
fully denature and were consequently impeded by the gel.

260 kDa

110 kDa

Figure 4.10: Western blot (a) stained with Ponceau S illustrating all protein bands on
membrane and (b) probed with rat tail type I collagen alpha-1 antibodies visualizing
collagen positive bands. Lane 1 is the pre-stained molecular weight standard. Lanes 2, 4
and 6 contain Sigma-Aldrich as purchased collagen, and lanes 3, 5 and 7 contain purified
rat tail collagen in decreasing amounts of 40 pg, 20 pg, and 10 pg, respectively.

4.6 Preparation o f Core-shell Type I Collagen Fibres
Following the successful isolation and purification of collagen, the next objective was to
create solid and core-shell nanofibres via electrospinning. Unless otherwise stated, our
isolated collagen was used to prepare electrospun collagen samples. Stabilized solid
collagen nanofibres were prepared using a 5 wt% type I collagen solution, as previously
established [111]. Initial attempts to produce solid fibres used a flow rate of 0.15 ml/hr
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with a voltage of 24 kV and a distance of 15 cm; the fibres were imaged and are shown in
Figure 4.11.

200 300 400 500
Fibre Diameter (nm)
Figure 4.11: SEM images of solid type I collagen nanofibres that exhibited a ribbon like
structure (scale bar = 2 pm for top images, 1 pm for bottom image). The average fibre
diameter was 349 ±141 nm (n = 150).
Samples exhibited a flat appearance with ribbon-like structures with an average fibre
diameter of 349 ±141 nm. The presence of flat fibres caused broadening of the diameter
distribution. Normally, the solvent evaporates during electrospinning uniformly yielding
cylindrical fibres. Ribbons are produced when the solvent evaporates too quickly, causing
the surface to harden and the fibre to collapse upon itself [117]. To overcome this, the
flow rate was raised to 0.25 ml/hr and the voltage was lowered to 18 kV. This yielded
fibres with a more cylindrical appearance, and a smaller average diameter and diameter
distribution of 256 ± 48 nm (Figure 4.12).
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Figure 4.12: SEM images of solid type I collagen nanofibres (scale bar = 5 pm). Fibre
diameter distribution determined average fibre diameter was 256 ± 48 nm (n = 250).
Once fibres were successfully produced, the effect of electrospinning on the collagen
structure was evaluated using FTIR. Both Sigma and our purified collagen were
electrospun and IR spectra of the nanofibrous meshes were obtained; a comparison of
electrospun collagen to that of the pre-processed collagen is shown in Figure 4.13. The
strong peaks corresponding to the amide groups are still present; however, there are
several small peaks present in the electrospun samples in the 1000 - 600cm'1 region.
These peaks, summarized in Table 4.3, correspond to the solvent HFIP (IR spectra in
Appendix K). The HFIP may not have had enough time to fully evaporate because the
samples were analyzed very shortly after spinning. Given the volatility of HFIP (boiling
point of 58.2°C) it is reasonable to expect that it will evaporate over time. Furthermore,
samples of electrospun collagen from previous group members that had given enough
time between sample preparation and FTIR reading did not show these peaks [118].
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Figure 4.13: FTIR spectra comparing rat tail collagen samples (Sigma-Aldrich and
purified samples) before electrospinning and as electrospun fibrous mats. * Peaks are
attributed to HFIP.
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Table 4.3 - Assignment of Additional Peaks Present in Electrospun Collagen Samples
Wave number (cm1)
HFIP

Electrospun Sigma Fibres

Electrospun Purified Collagen Fibres

1188

1182

1180

1107

1101

1101

894

896

894

842

846

842

738

734

736

684
684
688
*HFIP reference points were taken from SDBSWeb: http://riodb01.ibase.aist.go.ip/sdbs/
(National Institute of Advanced Industrial Science and Technology, June 10, 2011)
Following the production of solid collagen nanofibres, the subsequent step was to use
collagen as the shell polymer during coaxial electrospinning. The polymer shell
concentration was kept at 5 wt %; however a new core solution needed to be developed.
This was because electrospun collagen fibres dissolve in aqueous solutions if they are not
crosslinked, so the core solution had to have minimal water content. Ethanol was selected
to be the core solution solvent because collagen is insoluble in ethanol, which would help
establish a distinct core-shell structure. In addition, PEG was also added to the core
solution to increase its viscosity and make it more suitable for electrospinning. Finally, a
fluorescently tagged protein, BSA-FITC or BSA-Alexa Fluor 594, was incorporated as
well so that the successful encapsulation of the protein in the fibres could be imaged
using LSCM. Initially concentrations of 95% ethanol were used; however, the PEG and
BSA were not able to fully dissolve with such little water content. Water was added
slowly until the solutes were able to dissolve, resulting in a core solution of 80-90 %
ethanol.

The initial parameters chosen for coaxial electrospinning of type I collagen were the
same as those established in the PCL-BSA system (OFR = 0.3 ml/hr, IFR = 0.1 ml/hr).
However, it became evident that these rates were too high and were lowered to outer and
inner rates of 0.24 ml/hr and 0.08 ml/hr. It is important to note that the ratio of the flow
rates was always kept constant at 3:1. This produced fibres that appeared wet with lots of
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beads, so the flow rates were lowered to 0.18 ml/hr (outer) and 0.06 ml/hr (inner). These
rates yielded fibres with a smoother appearance and were subsequently sent for TEM and
LSCM imaging (Sigma collagen). The TEM images (Figure 4.14) revealed a welldefined core-shell structure where the solid portion of the fibres only contained type I
collagen. Fibres of this composition have not been reported in literature.

Figure 4.14: TEM images of type I collagen-BSA-FITC core-shell nanofibres (a-c) and
solid collagen fibres (d). The average outer and inner fibre diameters are 204 ± 73 nm
and 87 ± 33 nm respectively (n = 25).
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Collagen is unique in that it is naturally fluorescent, and unfortunately its fluorescence
overlaps that of the FITC dye used in these trials, thus no confocal images could be
obtained using the BSA-FITC containing fibres. Another fluorescent dye conjugated to
BSA used in these experiments was the Alexa 594 Fluor, which emits at a higher
wavelength in the red (620 nm). Confocal images were obtained, located in Figure 4.15,
however collagen’s strong and broad auto-fluorescence also interfered with this dye. To
balance the fluorescence interference from collagen, the threshold was lowered, but it
made it very difficult to resolve the fibres in the images. Despite the poor resolution, the
resulting image in Figure 4.15 did confimi the successful incorporation of the Alexa 594
fluor tagged BSA into the core of the collagen fibres.

Figure 4.15: LSCM image of type I collagen-BSA-Alexa Fluor 594 core-shell nanofibres
(scale bar = 10 pm).
The average diameter of the solid collagen nanofibres produced in this work were 256 ±
48 nm, which is comparable to values from the literature that range from 100-400 nm
[91-92]. Currently, most studies do not electrospin collagen directly into fibres; rather
they blend it with another, usually synthetic, polymer to increase the biocompatibility of
the nanofibres. Some examples of electrospun collagen polymer blends include: collagenPLA-nanocrystalline hydroxyapatite composite for bone tissue regeneration, PLGA-silk
fibroin-collagen for nerve tissue engineering, and collagen-poly(l-lactic acid)-copoly(caprolactone) for stem cell differentiation [119-121], Although this approach
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generates stable collagen containing fibres, scaffolds from these fibres would not have
the same properties as those derived from collagen alone.

Core-shell nanofibres composed of type I collagen shell have not been demonstrated in
the literature. The average outer and inner fibre diameters of the hollow type I collagen
nanofibres were 204 ± 73 nm and 87 ± 33 nm respectively. There have been few studies
published that have used collagen for coaxial electrospinning; however, all of those
studies have a synthetic polymer as the core. Essentially, coaxial electrospinning is used
as a method of depositing collagen on the surface of synthetic polymeric nanofibres, and
examples include thermoplastic polyurethanes and PCL [122-123]. One notable study
used coaxial electrospinning to coat collagen onto hollow PCL composite fibres creating
nanofibres with three distinct components [110]. Although this approach can be used to
increase the biocompatibility of synthetic scaffolds, controlled release from these fibres
would not be applicable.

The core-shell collagen nanofibres demonstrated in this work are novel and have multiple
applications in the biomedical field. The fibres can be made into scaffolds for tissue
engineering and, since they are hollow, they can be used as a controlled delivery device
for drugs, genes and proteins. This material lays the foundation for an ideal scaffold
composed of a biocompatible, bioactive material. By encapsulating and releasing
signalling molecules, like growth factors or cytokines, from inside the fibres a scaffold
system can be designed to activate and regulate specific cellular responses, like cell
adhesion, proliferation, migration and stem cell differentiation.

4 . 7 Concluding Remarks
The main objective of this work was to create core-shell nanofibres composed type I
collagen and encapsulated growth factors; unfortunately these fibres have yet to be
developed. However, several methods have been established that are necessary to
complete in order to achieve this goal. A method for isolating and purifying type I
collagen from rat tails has been validated and solid nanofibres composed of our purified
collagen have been prepared. Core-shell nanofibres composed of either PCL or type I
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collagen as the shell and encapsulated model protein BSA have been developed.
Furthermore, controlled release from PCL-BSA scaffolds has been demonstrated and a
thorough understanding of protein release from PCL core-shell fibres has been
established. Following this work, encapsulation and release of PDGF-bb from PCL can
be examined using the ELISA protocol developed in this work. Concurrently, in-vitro
studies comparing the performance of PCL-PDGF scaffolds to PCL-BSA scaffold can be
evaluated using the culturing and staining protocols developed here. Next, this system
would be adjusted such that encapsulation and release of BSA and PDGF-bb from type I
collagen could be examined and in-vitro studies performed.
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Chapter 5: Conclusions and Future Work
5.7

Conclusions

Protein encapsulation within core-shell nanofibres was successfully demonstrated. Fibres
composed of PCL and encapsulated BSA or BSA-FITC were electrospun and had an
average diameter of 1069 ± 388 nm. Scaffolds composed of PCL-BSA, with an average
weight of 3.6 ± 0.3 mg, containing an average of 62.7 ± 5.7 pig of BSA were able to
deliver approximately 22.2 ± 1.4 pg of BSA, or 35.3 ± 2.2 % of the theoretical loaded
protein over 10 days at 37 °C. It was found that protein release from PCL-BSA scaffolds
demonstrated Fickian diffusion profiles based on a cylindrical geometry. Additionally,
the inclusion of PEG within the core solution during coaxial electrospinning has been
demonstrated as a viable method for controlling protein release kinetics from hollow
nanofibres. Finally, these scaffolds were tested in-vitro and were able to maintain cell
adhesion and proliferation over three days.

A method for isolating and purifying type I collagen from rat tails has been developed.
The purity and quality of the isolated collagen is comparable to currently available
commercial products. This was validated via infrared spectroscopy and western blotting,
which generated data equivalent to that in the literature. In turn, the isolated collagen
samples were used to prepare solid collagen fibres with an average diameter of 256 ± 48
nm. The FTIR spectra of the electrospun fibres were found to have maintained the same
peaks after electrospinning compared to the isolated pre-spun collagen.

Finally, and most significantly, core-shell nanofibres composed of type I collagen and
BSA encapsulated have been prepared. These fibres had an average fibre inner and outer
diameter of 87 ± 33 nm and 204 ± 73 nm respectively, as determined from TEM images.
These fibres are an ideal substrate for TE because they would be biocompatible,
biodegradable and capable of localized protein delivery.
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5.2 Future Work
This study has demonstrated that controlled release from a tissue engineered scaffold is
capable. The next step from this work is to elucidate and analyze the release of PDGF-bb
from PCL core-shell fibres using the previously developed ELISA protocol. Next, other
growth factors, such as transforming growth factor beta or basic fibroblast growth factor,
can be encapsulated in a PCL shell. The release kinetics can be analyzed and their
performance in-vitro evaluated. Furthermore, scaffolds can be made with random and
aligned nanofibre patterns to better mimic the native leaflet layers the ventricularis and
fibrosa respectively.

The next stage would be to make these bioactive scaffolds more biocompatible by using
native valve ECM components, like type I collagen and hyaluronic acid, as the polymer
shell. As demonstrated in this work, core-shell type I collagen fibres can be created;
however, because collagen is soluble in media, the fibres need to be crosslinked to
increase their stability. Crosslinking will have to be experimentally investigated to
determine optimal degree of crosslinks needed to maintain stability but not crosslink the
proteins in the core. Once a reliable crosslinking protocol has been established, controlled
release from the scaffold can be evaluated. It is hypothesized that scaffolds with higher
degree of crosslinking will have slower release rates. Thus, scaffolds with varying
degrees of crosslinking will need to be compared to determine if and how much influence
crosslinking has on the release rate. Determining how crosslinking effects release rate can
be beneficial for these studies because the release kinetics can be optimized to mimic that
of natural tissue regeneration.

Finally, the core-shell collagen scaffolds would be evaluated in-vitro. They will be
assessed in terms of cell proliferation and migration through a variety of cell viability
assays. Additionally, cell phenotype and gene expression can be monitored using real
time polymerase chain reaction (RT-PCR). It is anticipated that the bioactive collagengrowth factor scaffold will allow cells to penetrate and grow deep within the fibrous
scaffold, and ultimately lead to an improved aortic heart valve replacement.
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Appendices
Appendix A - Buffers and ELISA Solutions
IX (100 mMj Phosphate Buffered Saline (PBS)
1) Combine the following in 1 litre of distilled water:
-

1.150 g Sodium phosphate dibasic heptahydrate (8.1 mM)

-

8.006 g Sodium Chloride (137 mM)

-

0.204 g Potassium phosphate monobasic (1.5 mM)

-

0.201 g Potassium Chloride (2.7 mM)

2) Adjust pH to 1.2-1 A
1.5 M Tris Buffered Saline (TBS)
1) Combine the following in 1 litre of distilled water:
-

8.80 g Sodium Chloride (137 mM)

-

3.0 g TRIS (tris (hydroxy methyl) aminomethane) Base (1.5 mM)

-

0.201 g Potassium Chloride (2.7 mM)

2) Adjust pH to:
-

7.4-7.6 with concentrated hydrochloric acid (HC1)

-

8.8 with concentrated sodium hydroxide (NaOH)

IX (100 mM) Tris Buffered Saline with TWEEN (TBS-T)
1) Add 500 pL Tween-20 (0.05%) to 1 litre of TBS.
2) Adjust pH to 7.4-7.6
4X Loading Buffer (Laemmli Buffer)
1) Combine the following:
-

2.0 ml of 1M Tris-HCl

-

0.8 g of SDS

-

4.0 ml of 100% glycerol

-

0.4 ml of 14.7 M (1-mercaptoethanol

-

8.0 mg bromophenol blue

2) Adjust pH to 6.8
3) Add water to a final volume of 10 mL.
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10X Running Buffer
1) Combine the following in 1 litre of distilled water:
— 30.3 g of Tris base
— 144.0 g of Glycine
— 10.0 g of SDS
2) Adjust pH to 8.3
Transfer Buffer
1) Add 200 mL of methanol to 800 mL litre of running buffer
Lysis Buffer
1) Combine the following with a final volume of 10 mL:
-

300 pi 5M NaCl

-

50 pi 1M Tris, pH 8.0

-

1 mL Glycerol

-

8.45 mL nanopure water

-

100 pi 10% SDS

-

Protease inhibitor (one pellet)

2) Turn on heat block to 95°C.
3) Put on ice to keep buffer cold.

ELISA Solutions
ELISA Wash Buffer
1) Add 500 pL of Tween® 20 (0.05%) in 1 L of IX PBS
2) Filter sterilize and adjust pH to 1.2-1A
PDGF-BB ELISA Reagent Diluent
1) Add 10.0 g of BSA (1.0 %) to 1 L IX PBS
2) Filter sterilize and adjust pH to 7.2-7.4
Substrate Solution - ELISA Substrate Reagent Pack (DY999)
-

1:1 mixture of Colour Reagent A (H2O2) and B (Tetramethylbenzidine)

ELISA Stop Solution (2 N H 2 S O 4 )
-

Dilute 5.55 mL of 18 N H2SO4with distilled water to a final volume of 50 mL
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Appendix B - Isolation o f Type I Collagen from Rat Tails
1) Thaw frozen rats tails in 70% ethanol for 1 hour
2) Use scalpel to cut off tip of tail and expose white collagen fibres. Using forceps pull
out collagen fibres from tail and place in separate sterile dish.
3) Continue cutting rat tail in segments, exposing and pulling out fibres, ensuring to
clean fibres of contaminating tissue.
4) At this point, fibres can be stored at -20 °C or proceed to collagen solution.
5) Weigh out 4 g/L of fibres (approximately 5 tails) and soak in 200 mL of 70% ethanol
for 30 minutes with forceps.
6) Place fibres in sterile Petri dish and leave overnight in a tissue culture hood with UV

light on to sterilize fibres.
7) Prepare acetic acid solution (1 mL of concentrated acetic acid in 1 L of distilled
water) and filter sterilize.
8) Add 900 mL of acetic acid solution to collagen fibres in an autoclaved 1 litre flask

with sterile stir bar. Place on stirrer in cold room (at 4 °C) for 4-7 days to dissolve
collagen.
9) Centrifuge the solution at 11, 000 rpm (10, 000 g) for 2 hours at 4 °C with brakes on.
10) Collect supernatant in a sterile bottle and measure protein concentration using Sircol
Collagen Assay (should be 1-3 mg/mL)
11) Collagen solution can be stored at this point at 4 °C.
12) To obtain collagen protein powder, freeze small samples (-10-15 ml) overnight in a 20 °C freezer and lyophilize for 1-2 days.
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Appendix C - Cell Culture Protocols
PROTOCOL: Isolation of Porcine Radial Artery Cells
Reagents:
-

Medium M199 (Sigma Aldrich, cat # M4530)

-

M l99 (500 mL) + 10% Fetal Bovine Serum (FBS) (50 mL) + 1%
Penicillin/Streptomycin (P/S) (5 mL)

-

M199 (120 mL) + 0.08% Collagenase (0.0010 ± 0.0001 g) + 1% P/S (1.2 mL = 2
x 600 pL) + 0.25pg/mL Amphotericin B (120 pL = 2 x 60 p) - solution must be
sterile (filter)

Equipment:
-

Biohazard Bags

-

50 mL Culture tubes

-

Dissection tray

-

Sterile Forceps

-

Instruments for dissecting

-

Sterile petri dish

-

Scalpel handles and several #20 blades

How to get pig forelimbs:
1) Contact Sheri Van Lingen at CSTAR (x32358) Sheri.VanLingen@lhsc.on.ca and
ask her if/when they will be sacrificing some pigs. Tell her you are interested in
taking the forelimbs of those pigs (from the elbow down).
2) Leave a labeled cooler filled with ice in the dead animals room in Animal Care on
the day of the pig surgery. Retrieve the following day and use tissues.
3) Make sure you have prepared enough of your solutions before picking up the
forelimbs.
4) Make sure limbs remain on ice until you are ready to dissect out the radial arteries.
Protocol:
To be performed outside the tissue culture hood
1) Dissect out radial arteries and place each into a tube containing approx 40 mis of
Ml 99.
2) Remove arteries from the tube and place in a petri dish. Ensure extra fat tissues
are removed before transferring dish into the tissue culture hood.
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To be performed inside the tissue culture hood.
1) Mince arteries into 1mm3pieces with a pair of forceps and a #20 scalpel blade.
2) Place pieces in a new tube containing 40mls of M l99 + 0.08% Collagenase + 1%
P/S + 0.25pg/mL Amphotericin B solution.
3) Incubate at 37°C for 24 hours, inverting several times throughout the 24 hours.
4) Centrifuge culture tubes for 5 minutes at 1250 RPM.
5) Remove supernatant leaving arteries pieces at the bottom.
6) Plate individual tissue pieces on 3-100mm2 dishes with lOmls of M l99 + FBS +

P/S.
7) Monitor for cellular outgrowth and remove tissue pieces once sufficient
outgrowth has occurred (Approx. 7 days)

PROTOCOL: Thawing Porcine Radial Artery Cells
1) Warm media (DMEM + 10% FBS + 1% P/S) in water bath (35°C, temperature is
critical), sterilize using 70% ethanol and place in tissue culture hood
2) Remove frozen cryotube from -80°C freezer
3) Warm cryotube in water bath (35°C, temperature is critical) until mostly thawed
(some ice crystals should be visible)
4) Wipe down cryotube with 70% ethanol before placing in tissue culture hood
5) Use the large (blue) micropipette to transfer the contents of the cryotube (lmL)
into a 15mL Falcon tube
6) Quickly add approximately 9 mL of media to tube

7) Centrifuge tube for 5 min. at 1250 RPM
8) Remove tube and use glass pipette to suction out as much of the supernatant as

possible, leaving the entire pellet (cells) at the bottom
9) Add 9 mL of media to the tube
10) Resuspend the pellet my continuously pipetting and dispensing the media.
Be careful not to spill the media while doing this as the tube cannot accommodate
all o f the liquid and the volume displaced by the pipette.
11) Transfer all of the contents from the tube into three 100mm2dishes (3 mL/dish)
12) Add 7 mL of media to each dish and incubate at 37°C, 5% CO2
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PROTOCOL: Counting Cells Using a Hemocytometer
1) Clean hemocytometer and cover slip using a kim wipe and 70% ethanol
2) Use pipette to extract 20 pL of cells in solution (after re-suspending them post
centrifugation)
3) Insert 20 pL into well next to coverslip (direct towards centre of plate)
4) Count areas 1 - 4 (Include cells on top and right-hand border of each area)
To calculate the number of cells/well:
Average cell = (# cells in areas 1-4) x 104
4
Volume/well = Number of cells/well
Average # cells

PROTOCOL: Fixing and Staining of Radial Artery Cells on Scaffolds
1) Remove media from wells and wash with PBS.
2) Fix using a 10% Formalin solution (3.7% formaldehyde in PBS) for 10 minutes.
Wash with PBS and repeat two more times.
3) Prepare mounting media with 500 pL of Vectashield and 500 pL of Hoechst
33342. Vortex to ensure proper mixing.
4) Using sterile forceps gently remove scaffolds from holder and place onto sterile
microscope slide.
5) Add -100 pL of mounting media onto scaffold and top with sterile cover slip.
6) Allow to settle for 10 minutes then image. Can be stored at 4 °C and imaged later.
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Appendix D - Theoretical Protein Loading Calculations
These are sample calculations using a 12 wt% PCL in TFE solution for the shell, and 10
mg/mL BSA with 20 wt% PEG in PBS for the core. Assumptions made in calculations
are: spinning time is constant for both inner and outer pumps and the mass ratio is
constant throughout scaffold.
BSA

PEG

PCL
Flow Rate (mL/hr)
Concentration (mg/mL)
Mass (mg/hr)
Total Mass (Assume 1 hr)

0.3
120
36
57

0.1

0.1

200
20

10
1

Fraction Scaffold Mass
Percent Scaffold Mass (%)

0.6316
63.16

0.3509
35.09

0.0175
1.75

3.158
3158

1.754
1754

0.0877
87.7

Example: Scaffold mass = 5 mg
Mass (mg)
Mass (ng)
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Appendix E - Bradford Assay and Standard
The Bradford assay is protocol used to determine the amount of protein in sample using
its absorbance, and is calculated according to Beer’s law, A = sic, where 1 is the path
length (1 cm), e is the molar extinction constant and c is the concentration (pg/mL). This
experimental setup is for a 96-well plate with a final volume of 200 pL.

1) Prepare BSA protein standards according to the following chart:
[BSA]
Voi Buffer2
Voi. Standard1 (pL)
Voi Dye34(pL)
(pg/mL)
(pL)
0
0
160
40
0.5
10
150
40
1
20
140
40
2
40
120
40
4
80
80
40
6
120
40
40
8
160
0
40
'Standard is 10 pg/mL BSA
2Buffer is IX PBS
3Dye is the Bradford Reagent, Coomassie Brilliant Blue G-250
2) Create a standard curve by measuring the absorbance at 595 nm and plotting
absorbance as a function of time.

Bradford Standard Curve

3) Perform a linear regression, and derive formula to solve for unknown concentration
from absorbance.
4) Measure absorbance of samples and solve for the concentration.
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Appendix F - Enzyme Linked Immunosorbant Assay (ELISA) Protocol
ELISA Protocol for PDGF-BB
Step 1: Coat
Capture Ab (840925), 0.4 pg/mL in PBS (IX)
For one plate, 61.11 uL of 72 pg/mL Capture Reagent in 10938.89 uL PBS (11 mL total),
dispense 100 pL/well. Cover plate with parafilm and incubate at room temperature
overnight (or in fridge up to one week). Wash 3X - Wash buffer, 400 pL per well

Step 2: Block
Reagent Diluent 300 pL per well. Incubate at room temperature for one hour. Wash 3X Wash buffer, 400 pL per well

Step 3: Standards and samples
Dilute standards and samples in Reagent Diluent
Standard curve serially diluted (2-fold) from 2000 pg/mL, for 1 plate 12 pL of 110
pg/mL PDGF-BB (840927) in 648 pL Reagent Diluent. Dilutions are done in
polypropylene plate and then transferred to polystyrene plate, 100 pL/well
Incubate at room temperature for two hours. Wash 3X - Wash buffer, 400 pL per well

Step 4: Biotinylation
Detection Ab (840926), 400 ng/mL in Reagent Diluent
For one plate, 61.11 uL of 50 pg/mL Detection Antibody in 10938.89 pL Reagent
Diluent (11 mL total), dispense 100 pL/well. Incubate at room temperature for two hours
Wash 3X - Wash buffer, 400 pL per well

Step 5: Biotin dectection
Streptavidin - HRP, (890803), 1:200 dilution in Reagent Diluent
For one plate, add 55 pi of HRP Streptavidin to 10.45 mL Reagent Diluent (11 mL total),
dispense 100 pL/well, Incubate at room temperature for 20 minutes. Wash 3X - Wash
buffer, 400 pL per well
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Step 6: Colour development
TMB kit, (R&D DY999 - in fridge), mix 5.5 mL vial A + 5.5 mL vial B, use immediately
100 pL per well, Incubate for 20 minutes

Step 7: Stop
2N H2SO4, add 27.75 mL 18N H2SO4to 225.25 mL dt^O (in acid cabinet)
50 pL per well pipetted in the same order as previous step. Read plate immediately

Step 8: Read
Microplate reader at 450 nm and at 540 or 570 nm (to subtract for correction)
Zero - read blank wells and set average value to first well

Step 9: Plot
Plot the absorbance difference (ABS450 -

ABS570/540)

against known concentration using a

four parameter logistic plot. Calculate concentration from sample absorbencies.
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Appendix G - SDS-PAGE and Western Blotting
Total Protein Collection
Procedure:
1. Prepare fresh Lysis Buffer and put on ice.
2. 500 pg of each solid collagen was dissolved 400 pi of the lysis buffer.
3. Homogenized the samples with tissue homogenizer (Ultra Turrax T25
homogenizer, IKA Laboratory Equipment) for 2-3 minutes each
4. Sonicate the samples on ice (Model 500 Dismembrator, Fisher Scientific) for 20s
total (in pulses of 5s on 2s off) at 30% amplitude.
5. Finally, heat the samples to 95 degrees C for 3 minutes to get all collagen into
solution.
SDS-PAGE
Preparation:
1. Ensure all required buffers are made and are still good.
2. From the BCA protein counts, work out how many pi of sample must be loaded to
load 50pg of protein.
3. Determine the size of proteins that will be probed for and decide what % of
acrylamide is required for best resolution of those size proteins.

Procedure:
1. Take out protein samples and size standard to thaw on ice.
2. Clean Glass plates and combs. Clean and wipe plates with Windex, rinse residue
with distilled water, and finally wipe clean with 70% alcohol. Wipe combs with
alcohol to remove any old acrylamide.
3. Assemble gel apparatus as per manufacturer’s instructions.
4. Prepare 1.5% APS fresh (0.15g per lOmL water)
5. Prepare lOmL Separating Gel per apparatus used
Component
1.5M Tris, pH 8.8
10% SDS

6% gel
(>100kDa)
2.5 mL

8% gel
(60-100kDa)
2.5 mL

10% gel
(40-60kDa)
2.5 mL

200 pi

200 pi

200 pi
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f

30% Acrylamide mix

2.0 mL

2.7 mL

3.3 mL

Autoclaved H2O

4.64 mL

3.93 mL

3.33 mL

655 pi

655 pi

655 pi

5 pi

5 pi

5 pi

1.5% Ammonium Persulfate
TEMED

* mix solution gently by inversion before adding APS and again before adding
TEMED. Invert gently a few times before pipetting between glass plates. Ensure
0.1% SDS overlay is ready to be added immediately.
6. Quickly add acrylamide solution between plates via pipetting to approximately Vi cm

below where the comb will sit. On the Mini-Protean 3 this is just to the bottom of the
green cross bar behind the glass plates.
7. Immediately and gently overlay the acrylamide with 0.1% SDS buffer.
8. Allow gel to set for 45 minutes to an hour.

9. During gel hardening, prepare the loading samples (on ice):
•

Figure out which sample requires the most loading volume, and round up to the
nearest multiple of 5. This volume figured is now the Loading Volume.

•

Prepare loading samples by taking the volume from the stock tube required for
50pg of protein (figured in Preparation step 2) and adding enough lx Loading
Buffer (in fridge) to bring up volume to the calculated Loading Volume.

•

Because the protein was boiled on collection it doesn’t need to be boiled now. If
the protein has not been boiled yet it can be heated at 95°C for 5 minutes and put
on ice now.

10. Once the Separating Gel has hardened, pour off the SDS overlay and wash the top of
the gel with water. Tip casting stand on its side to drain water and blot out any
remaining water with folded paper towel. Allow gel to air dry while preparing the
Stacking gel.
11. Prepare the Stacking Gel (one 5mL preparation enough for two stacking gels):
83Op 130% acrylamide
3.0mL autoclaved H2O
63Op11.0M Tris, pH 6 8
200pl 10% SDS
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* mix solution gently at this point and add the following reagents one at a time,
mixing gently by inversion between additions.
332p i 1.5% APS
8p i TEMED
12. Quickly add Stacking gel to the remaining space on top of the Separating gels. Set
the combs in place without introducing bubbles to the gel and allow to harden for 20
minutes.
13. Prepare 500mL of lx Running Buffer per 2 gels (i.e. 500mL per tank).
14. Measure out protein size standards as per manufacturer’s instructions (usually 5-10pl
of stock standard per gel) and dilute with lx Loading Buffer to the same loading
volume as samples.
15. Once Stacking Gels are set, pull out the comb carefully and wipe out any waste
acrylamide (it may be necessary to wash out the wells with Running Buffer to get any
excess acrylamide clear of the wells). Detach from the casting stand and wipe away
any excess gel.

Assemble into the gel apparatus according to manufacturer’s

instructions. Fill inner tank with Running Buffer and check for leaks.
16. Load samples and ladders as far from the outside lanes as possible, loading lx
Loading Buffer in any unused wells.
17. Place apparatus in tank and fill outside with remaining Running Buffer. Place lid on
(check polarity is correct) and connect leads to power pack.
18. Run at 130V for as long as it takes for protein of interest (tracked by position of size
standards) to be in the bottom half of the gel (usually about an hour).
19. During the run, cut lx nitrocellulose membrane and 4x Whatman filter paper per gel
(size using spare plates or sponges). Prepare 1L lx Transfer Buffer (+20% methanol)
per 2 gels and chill at 4°C.
20. Once the run is complete, pour ~500mL of Transfer Buffer into each of 2 trays.
Using a dull pencil, label the nitrocellulose membrane. In one tray soak one sponges,
3 filter papers and 1 nitrocellulose membrane (pre-wet this with water before placing
in buffer). In the other tray place the sandwich apparatus with the black side down
and place one sponge on the black side. Place one filter paper on top of the sponge.
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Take out the gel apparatus and empty Running Buffer into the sink. Rinse out the
tank with tap water.
21. Disassemble gel apparatus and carefully separate glass plates (keep the gel on the
larger plate). Use a razor or a blunt scraper to remove the stacking gel from the
separating gel.
22. Place a soaked piece of filter paper onto the gel as it sits on the larger plate (without
introducing air bubbles if possible). Invert the plate and gently use the blade/scraper
to ease the gel onto the filter paper. Place the filter paper and gel (with the well side
pointing to the top of the apparatus) onto the sandwich apparatus.
23. Place the soaked nitrocellulose onto the gel label side facing the gel. Cover with two
more filter papers and the remaining sponge.
24. With a broken plastic pipette, gently roll out any air bubbles from the stack. Then
clamp the sandwich together and place into the other tray of buffer (i.e. keep it wet
while preparing other transfers). Repeat steps for all remaining gels.
25. Once all sandwiches prepared, place into transfer apparatus with the black side of the
sandwich facing the black half of the apparatus. Replace the top (ensuring polarity is
correct) and place assembled tank into a Styrofoam ice box.
26. Pack the tank in ice and fill ice box with water to halfway up the tank. Run the
transfer for 1 hour at 75V (alternatively, transfer can be done at 30V overnight while
stirring the buffer, but there is a risk of transferring small proteins right through the
membrane).
27. Once transfer is complete, disassemble and toss everything except for the
nitrocellulose membrane. Cut this to the imprint of the gel along the top and bottom
and place in lx TBS. Two membranes can occupy the same dish of TBS, but cannot
be facing each other (protein side must face out).
28. Once all membranes are collected, fill 3 containers with 1) Ponceau S solution, 2)
Water and 3) TBS. Stain one blot at a time in Ponceau S (a few seconds is enough),
then destain in water until bands can be seen. Note condition of the protein bands and
apparent evenness of loading, and place blot in TBS to remove the stain.
29. Blots may be kept in TBS at 4°C for no more than 48 hours prior to Blotting.
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Western Blotting
Preparation:
1. Make lx TBS and lx TBS-T (TBS + 0.05% Tween-20)
2. Make enough 5% non-fat dried milk (NFDM)(in TBS-T) for 30mL per blot.

Procedure:
1. Pour off TBS storage buffer and add lOmL NFDM to block non-specific binding.
Rock for 1 hour at room temperature (rock across width of the blot not the length).
2. Make a dilution of primary antibody in 10 mL NFDM solution as appropriate
(starting dilutions usually found on product sheets).
3. After blocking completed, pour off blocking solution and add milk containing
primary antibody. Rock for 1 hour at room temperature or overnight at 4°C.
4. After 1 hour, pour off primary solution and wash 4x 5 minutes with TBS-T.
5. Prepare appropriate dilution of secondary antibody (1:10,000 usually a good starting
point) in 10 mL NFDM.
6. After final TBS-T wash, add secondary solution and rock for 1 hour at RT.
7. After incubation, wash 3x 5 minutes with TBS-T and lx 5 minutes with TBS.
8. During TBS wash prepare lOmL of Supersignal for every 2 blots (according to
manufacturer’s instructions).
9. Pour TBS from half of the containers and add Supersignal solution. Rock 5 minutes.
Once complete, pour TBS off the remaining half of the blots and pour in the used
Supersignal solution (i.e. one lOmL preparation of Supersignal is enough to treat two
separate blots). Incubate for 5 minutes
10. Immediately wrap the first set of blots in Saran Wrap to preserve Supersignal, while
the second set incubates.
11. Once the second set of blots is ready, remove them from Supersignal (keep the
solution though in case you need to rewet the membrane) and shake off the excess
solution. Wrap immediately in Saran Wrap.
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Appendix H

-

Supplementary PEG Data
Absorbance Spectra of BSA Solutions Containing
Increasing Amounts of PEG Present

♦ Inc BSA-No PEG

Inc BSA - PEG 500

A

Inc BSA - Inc PEG

Absorbance Spectra of PEG Solutions Containing

Influence of PEG on BSA Absorbance: Samples were analyzed using Bradford Assay
to determine concentration of BSA detected. Only one data point showed a significant
difference between the control (No PEG) samples with 500 pg/mL PEG (p = 0.0158).
PEG solutions demonstrated no significant increases in absorbance without the presence
of BSA. (Legend: Inc BSA - Increasing BSA from 0-25 pg/mL, No PEG - 0 pg/mL
PEG, PEG 500 - 500 pg/mL PEG, Inc PEG - Increasing PEG from 0-400 pg/mL, No
BSA - 0 pg/mL BSA, Constant BSA - 4 pg/mL).
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Appendix I

-

Preliminary ELISA Data
Initial ELISA Results Validating PDGF Core
Solution Samples
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Final, Improved ELISA Test Results for Validation
of PDGF Core Solutions
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Comparison of ELISA DATA: Samples were analyzed using ELISA to determine
sample concentration. As can be seen, initial results were only recovering ~50 % of
PGDF purchased. After several troubleshooting efforts, sample concentrations and
accuracy of ELISA was improved to ~ 80 % (Legend: QC - Quality Control, PDGFSample, STD - Standard, 500 - 4000 - Concentration in pg/mL).
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Appendix J

-

IR Spectra for Multiple Collagen Samples

0.95

Transmittance
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Appendix K - I R Spectra for Hexafluoroisopropanol (HFIP)
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Image reprinted with permission for SDBSWeb: http://riodb01.ibase.aist.go.ip/sdbs/
(National Institute of Advanced Industrial Science and Technology, July 10, 2011)
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Appendix L Copyright Permissions
-

Circulation Copyright Permission -

Figure 2.1

WOLTERS KLUWER HEALTH LICENSE
This is a License Agreement between Erica EM Lee ("You") and Wolters Kluwer Health
("Wolters Kluwer Health") provided by Copyright Clearance Center ("CCC"). The
license consists of your order details, the terms and conditions provided by Wolters
Kluwer Health, and the payment terms and conditions.
License Number: 2704351326508
License date: Jul 08, 2011
Licensed content publisher: Wolters Kluwer Health
Licensed content publication: Circulation
Licensed content title:
Evolving Concepts of Cardiac Valve Dynamics:The Continuum of Development,
Functional Structure, Pathobiology, and Tissue Engineering
Licensed content author: Frederick J. Schoen
Licensed content date: Oct 28, 2008
Volume Number: 118
Issue Number: 18
Type of Use: Dissertation/Thesis
Requestor type: Individual
Title of your thesis / dissertation: Core-Shell Nanofibres for Heart Valve Leaflet Tissue
Engineering
Expected completion date: Aug 2011
Estimated size (pages): 100

Ultrasound in Medicine & Biology Copyright Permission
- Figure 2.2
This is a License Agreement between Erica EM Lee ("You") and Elsevier ("Elsevier").
The license consists of your order details, the terms and conditions provided by
Elsevier, and the payment terms and conditions.
License Number
2718851427827
License date
Jul 30, 2011
Licensed content publisher
Elsevier
Ultrasound in Medicine & Biology
Licensed content publication
Anisotropy of High-Frequency Integrated
Licensed content title
Backscatter from Aortic Valve Cusps
Zamir Khan,Derek R. Boughner,James C.
Licensed content author
Lacefield
L icensed content date

S eptem ber 2008
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Licensed content volume number
Licensed content issue number
Number of pages
Type of Use
Portion
Number of
figures/tables/illustrations
Format
Are you the author of this Elsevier
article?
Order reference number
Title of your thesis/dissertation
Expected completion date
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34
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Macromolecular Chemistry and Physics Copyright Permission
- Figure 2.6
This is a License Agreement between Erica EM Lee ("You") and John Wiley and Sons
("John Wiley and Sons"). The license consists of your order details, the terms and
conditions provided by John Wiley and Sons, and the payment terms and conditions.
License Number
2718350054133
License date
Jul 29, 2011
Licensed content publisher
John Wiley and Sons
Licensed content publication
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Ultrafine Electrospun Polyamide-6 Fibers:
Licensed content title
Effect of Solution Conditions on Morphology
and Average Fiber Diameter
Chidchanok Mit-uppatham,Manit
Licensed content author
Nithitanakul,Pitt Supaphol
Licensed content date
Nov 26, 2004
Start page
2327
End page
2338
Type of use
Dissertation/Thesis
Requestor type
University/Academic
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